JMLD personal page - To The Moon

JMLD

JMLD

JD

15Follow

1Followers

1Topic

0Badge

2021-07-01

$CEL-SCI Corp(CVM)$Hi allgive opinion..i am new on this stock. Should i sell or hold?

2021-04-21

Comment pls

Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more

2021-07-07

$CEL-SCI Corp(CVM)$letters for investor! Please read it.

2021-04-21

Pls response to my comment

Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more

2021-03-24

$Express,(EXPR)$hmmm,where gone the green days!

2021-08-09

$Globalstar(GSAT)$Hoping after Q2 Aug 2021 Earning reports is out,price will change as forecasted. Good luck!

2021-04-21

Tell me more

BRIEF-Bit Digital Reports New 40MW Agreement With Compute North

2021-07-21

Up..up..up on the way...????

2021-07-12

Is this dip just a momentum, after recent orders delivered?

2021-07-07

$CEL-SCI Corp(CVM)$Latest news updated.

2021-07-07

Great articles to shares

CEL-SCI Corporation Issues Letter to Shareholders

2021-07-07

Some updates here,hope its beneficial for holders and shareholders.

CEL-SCI Corporation Issues Letter to Shareholders

2021-07-01

?Great,really appreciate for such respond n comments..good wishes for all.

@Skyciti:$CEL-SCI Corp(CVM)$Hold…..it will rocket soon.

2021-07-01

$CEL-SCI Corp(CVM)$what happened? Should i hold or sell?

2021-05-05

$Canaan Inc.(CAN)$Not sure what canni do,hold or blood weeping!

2021-04-21

Tell me more

3 Stocks That Offer Explosive Potential Gains

2021-04-21

How?

Three indirect ways investors can play the cryptocurrency craze

2021-04-21

Say it again

Should You Buy Peloton Stock: What To Consider

2021-04-21

Love this

3 Stocks That Offer Explosive Potential Gains

2021-04-21

Bring me the moon!

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3573389351985325","uuid":"3573389351985325","gmtCreate":1610304554064,"gmtModify":1618798374751,"name":"JMLD","pinyin":"jmld","introduction":"","introductionEn":"","signature":"JD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":15,"tweetSize":26,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.69%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":898034101,"gmtCreate":1628449035103,"gmtModify":1703506275696,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GSAT\">$Globalstar(GSAT)$</a>Hoping after Q2 Aug 2021 Earning reports is out,price will change as forecasted. Good luck!","listText":"<a href=\"https://laohu8.com/S/GSAT\">$Globalstar(GSAT)$</a>Hoping after Q2 Aug 2021 Earning reports is out,price will change as forecasted. Good luck!","text":"$Globalstar(GSAT)$Hoping after Q2 Aug 2021 Earning reports is out,price will change as forecasted. Good luck!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898034101","isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178844705,"gmtCreate":1626802004807,"gmtModify":1703765532381,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Up..up..up on the way...????","listText":"Up..up..up on the way...????","text":"Up..up..up on the way...????","images":[{"img":"https://static.tigerbbs.com/d7c09624f7153c0394e2cdc30065185e","width":"1600","height":"1911"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178844705","isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":146836492,"gmtCreate":1626064895516,"gmtModify":1703752659982,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Is this dip just a momentum, after recent orders delivered?","listText":"Is this dip just a momentum, after recent orders delivered?","text":"Is this dip just a momentum, after recent orders delivered?","images":[{"img":"https://static.tigerbbs.com/1f5e7d1e70be72971e28865eb179bb03","width":"1600","height":"2895"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146836492","isVote":1,"tweetType":1,"viewCount":337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":140472037,"gmtCreate":1625670771129,"gmtModify":1703746199206,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Latest news updated.","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Latest news updated.","text":"$CEL-SCI Corp(CVM)$Latest news updated.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140472037","isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140473027,"gmtCreate":1625670618569,"gmtModify":1703746193035,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>letters for investor! Please read it.","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>letters for investor! Please read it.","text":"$CEL-SCI Corp(CVM)$letters for investor! Please read it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/140473027","isVote":1,"tweetType":1,"viewCount":1456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140447431,"gmtCreate":1625670536723,"gmtModify":1703746189889,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Great articles&nbsp; to shares","listText":"Great articles&nbsp; to shares","text":"Great articles to shares","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140447431","repostId":"2149397016","repostType":2,"repost":{"id":"2149397016","kind":"news","pubTimestamp":1625659200,"share":"https://ttm.financial/m/news/2149397016?lang=&edition=fundamental","pubTime":"2021-07-07 20:00","market":"us","language":"en","title":"CEL-SCI Corporation Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2149397016","media":"Business Wire","summary":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a","content":"<html><body><p><b>VIENNA, Va., July 07, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/CVM\">CEL-SCI Corp</a>oration<b> (NYSE American: CVM)</b> today issued a letter to its shareholders.</p>\n<p>Dear CEL-SCI shareholders:</p>\n<p>The purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.</p>\n<p><b><i>Very Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients</i></b></p>\n<p>On June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.</p>\n<p>Our Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus<b> </b>radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.</p>\n<p>That means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.</p>\n<p><b><i>The Study Design is Based on National Comprehensive Cancer Network</i> <i>(NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful</i></b></p>\n<p>Let me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.</p>\n<p>Patients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of &lt;0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.</p>\n<p><b><i>The Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding</i></b></p>\n<p>The analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.</p>\n<p>We have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.</p>\n<p><b><i>False Assertions Addressed </i></b></p>\n<p>Some false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact <a href=\"https://laohu8.com/S/AONE\">one</a> of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.</p>\n<p>We intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?</p>\n<p>We are talking about a clear long term statistically significant survival benefit in <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.</p>\n<p>Other false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.</p>\n<p><b><i>Support From the Independent Statistician</i></b></p>\n<p>We are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:</p>\n<p>(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)</p>\n<p><b><i>CEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been &gt;30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. </i></b></p>\n<p><b><i>The decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:</i></b></p>\n<ul>\n<li><b><i>The primary efficacy endpoint remains overall survival</i></b>\n<ul>\n<li><b><i>Efficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.</i></b></li>\n<li><b><i>Analysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study </i></b></li>\n<li><b><i>Survival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery</i></b></li>\n<li><b><i>Model results are robust: </i></b>\n<ul>\n<li><b><i>Statistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n<li><b><i>Statistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n</ul></li>\n</ul></li>\n<li><b><i>The study did not encounter any overall safety issues.</i></b>\n<ul>\n<li><b><i>Every one of the above analyses were prospectively defined in the SAP. </i></b></li>\n</ul></li>\n</ul>\n<p><b><i>P-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:</i></b></p>\n<ul>\n<li><b><i>Collecting additional data.</i></b></li>\n<li><b><i>Dropping aberrant data.</i></b></li>\n<li><b><i>Focusing on alternative measures.</i></b></li>\n<li><b><i>Changing the analyses method.</i></b></li>\n</ul>\n<p><b><i>Specifically: </i></b></p>\n<ul>\n<li><b><i>We collected the data pre-specified in the protocol and eCRF.</i></b></li>\n<li><b><i>We did not drop any data; we used the NCCN low risk definition and we used the ITT population.</i></b></li>\n<li><b><i>We focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).</i></b></li>\n</ul>\n<p><b><i>We followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.</i></b></p>\n<p><b><i>Based on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" </i></b></p>\n<p>We believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.</p>\n<p><b><i>Do Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?</i></b></p>\n<p>I believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?</p>\n<p>Uncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.</p>\n<p>We have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"<i>neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\"</i>.</p>\n<p><b><i>Closing</i></b></p>\n<p>In closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.</p>\n<p>In talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"</p>\n<p>Thank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.</p>\n<p>Sincerely,</p>\n<p>Geert Kersten<br/>Chief Executive Officer</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</p>\n<p><i>* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.</i></p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210707005476/en/</span></p>\n<p><b>Contacts</b></p>\n<p>COMPANY CONTACT:<br/>Gavin de Windt<br/>CEL-SCI Corporation<b> </b><br/>(703) 506-9460</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CEL-SCI Corporation Issues Letter to Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCEL-SCI Corporation Issues Letter to Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/nbtUTYW1SOiQDcaq8dPzOg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Lxq8Bg4KkcfIXxn6.npJFg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7486af1e6a88511bdd61fb03476b6e56","relate_stocks":{"CVM":"CEL-SCI Corp"},"source_url":"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149397016","content_text":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.\nVery Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients\nOn June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.\nOur Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.\nThat means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.\nThe Study Design is Based on National Comprehensive Cancer Network (NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful\nLet me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.\nPatients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of <0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.\nThe Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding\nThe analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.\nWe have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.\nFalse Assertions Addressed \nSome false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact one of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.\nWe intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?\nWe are talking about a clear long term statistically significant survival benefit in one of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. Two different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.\nOther false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.\nSupport From the Independent Statistician\nWe are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:\n(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)\nCEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been >30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. \nThe decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:\n\nThe primary efficacy endpoint remains overall survival\n\nEfficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.\nAnalysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study \nSurvival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery\nModel results are robust: \n\nStatistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates\nStatistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates\n\n\nThe study did not encounter any overall safety issues.\n\nEvery one of the above analyses were prospectively defined in the SAP. \n\n\nP-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:\n\nCollecting additional data.\nDropping aberrant data.\nFocusing on alternative measures.\nChanging the analyses method.\n\nSpecifically: \n\nWe collected the data pre-specified in the protocol and eCRF.\nWe did not drop any data; we used the NCCN low risk definition and we used the ITT population.\nWe focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).\n\nWe followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.\nBased on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" \nWe believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.\nDo Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?\nI believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?\nUncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.\nWe have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\".\nClosing\nIn closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.\nIn talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"\nThank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.\nSincerely,\nGeert KerstenChief Executive Officer\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.\n* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210707005476/en/\nContacts\nCOMPANY CONTACT:Gavin de WindtCEL-SCI Corporation (703) 506-9460","news_type":1},"isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140446720,"gmtCreate":1625670384060,"gmtModify":1703746183945,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Some updates here,hope its beneficial&nbsp; for holders and shareholders.","listText":"Some updates here,hope its beneficial&nbsp; for holders and shareholders.","text":"Some updates here,hope its beneficial for holders and shareholders.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140446720","repostId":"2149397016","repostType":2,"repost":{"id":"2149397016","kind":"news","pubTimestamp":1625659200,"share":"https://ttm.financial/m/news/2149397016?lang=&edition=fundamental","pubTime":"2021-07-07 20:00","market":"us","language":"en","title":"CEL-SCI Corporation Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2149397016","media":"Business Wire","summary":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a","content":"<html><body><p><b>VIENNA, Va., July 07, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/CVM\">CEL-SCI Corp</a>oration<b> (NYSE American: CVM)</b> today issued a letter to its shareholders.</p>\n<p>Dear CEL-SCI shareholders:</p>\n<p>The purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.</p>\n<p><b><i>Very Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients</i></b></p>\n<p>On June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.</p>\n<p>Our Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus<b> </b>radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.</p>\n<p>That means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.</p>\n<p><b><i>The Study Design is Based on National Comprehensive Cancer Network</i> <i>(NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful</i></b></p>\n<p>Let me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.</p>\n<p>Patients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of &lt;0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.</p>\n<p><b><i>The Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding</i></b></p>\n<p>The analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.</p>\n<p>We have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.</p>\n<p><b><i>False Assertions Addressed </i></b></p>\n<p>Some false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact <a href=\"https://laohu8.com/S/AONE\">one</a> of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.</p>\n<p>We intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?</p>\n<p>We are talking about a clear long term statistically significant survival benefit in <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.</p>\n<p>Other false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.</p>\n<p><b><i>Support From the Independent Statistician</i></b></p>\n<p>We are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:</p>\n<p>(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)</p>\n<p><b><i>CEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been &gt;30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. </i></b></p>\n<p><b><i>The decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:</i></b></p>\n<ul>\n<li><b><i>The primary efficacy endpoint remains overall survival</i></b>\n<ul>\n<li><b><i>Efficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.</i></b></li>\n<li><b><i>Analysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study </i></b></li>\n<li><b><i>Survival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery</i></b></li>\n<li><b><i>Model results are robust: </i></b>\n<ul>\n<li><b><i>Statistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n<li><b><i>Statistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n</ul></li>\n</ul></li>\n<li><b><i>The study did not encounter any overall safety issues.</i></b>\n<ul>\n<li><b><i>Every one of the above analyses were prospectively defined in the SAP. </i></b></li>\n</ul></li>\n</ul>\n<p><b><i>P-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:</i></b></p>\n<ul>\n<li><b><i>Collecting additional data.</i></b></li>\n<li><b><i>Dropping aberrant data.</i></b></li>\n<li><b><i>Focusing on alternative measures.</i></b></li>\n<li><b><i>Changing the analyses method.</i></b></li>\n</ul>\n<p><b><i>Specifically: </i></b></p>\n<ul>\n<li><b><i>We collected the data pre-specified in the protocol and eCRF.</i></b></li>\n<li><b><i>We did not drop any data; we used the NCCN low risk definition and we used the ITT population.</i></b></li>\n<li><b><i>We focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).</i></b></li>\n</ul>\n<p><b><i>We followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.</i></b></p>\n<p><b><i>Based on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" </i></b></p>\n<p>We believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.</p>\n<p><b><i>Do Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?</i></b></p>\n<p>I believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?</p>\n<p>Uncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.</p>\n<p>We have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"<i>neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\"</i>.</p>\n<p><b><i>Closing</i></b></p>\n<p>In closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.</p>\n<p>In talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"</p>\n<p>Thank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.</p>\n<p>Sincerely,</p>\n<p>Geert Kersten<br/>Chief Executive Officer</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</p>\n<p><i>* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.</i></p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210707005476/en/</span></p>\n<p><b>Contacts</b></p>\n<p>COMPANY CONTACT:<br/>Gavin de Windt<br/>CEL-SCI Corporation<b> </b><br/>(703) 506-9460</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CEL-SCI Corporation Issues Letter to Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCEL-SCI Corporation Issues Letter to Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/nbtUTYW1SOiQDcaq8dPzOg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Lxq8Bg4KkcfIXxn6.npJFg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7486af1e6a88511bdd61fb03476b6e56","relate_stocks":{"CVM":"CEL-SCI Corp"},"source_url":"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149397016","content_text":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.\nVery Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients\nOn June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.\nOur Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.\nThat means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.\nThe Study Design is Based on National Comprehensive Cancer Network (NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful\nLet me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.\nPatients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of <0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.\nThe Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding\nThe analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.\nWe have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.\nFalse Assertions Addressed \nSome false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact one of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.\nWe intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?\nWe are talking about a clear long term statistically significant survival benefit in one of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. Two different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.\nOther false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.\nSupport From the Independent Statistician\nWe are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:\n(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)\nCEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been >30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. \nThe decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:\n\nThe primary efficacy endpoint remains overall survival\n\nEfficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.\nAnalysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study \nSurvival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery\nModel results are robust: \n\nStatistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates\nStatistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates\n\n\nThe study did not encounter any overall safety issues.\n\nEvery one of the above analyses were prospectively defined in the SAP. \n\n\nP-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:\n\nCollecting additional data.\nDropping aberrant data.\nFocusing on alternative measures.\nChanging the analyses method.\n\nSpecifically: \n\nWe collected the data pre-specified in the protocol and eCRF.\nWe did not drop any data; we used the NCCN low risk definition and we used the ITT population.\nWe focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).\n\nWe followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.\nBased on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" \nWe believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.\nDo Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?\nI believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?\nUncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.\nWe have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\".\nClosing\nIn closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.\nIn talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"\nThank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.\nSincerely,\nGeert KerstenChief Executive Officer\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.\n* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210707005476/en/\nContacts\nCOMPANY CONTACT:Gavin de WindtCEL-SCI Corporation (703) 506-9460","news_type":1},"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158685664,"gmtCreate":1625147852158,"gmtModify":1703737157271,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"?Great,really appreciate&nbsp; for such respond n comments..good wishes for all.","listText":"?Great,really appreciate&nbsp; for such respond n comments..good wishes for all.","text":"?Great,really appreciate for such respond n comments..good wishes for all.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158685664","repostId":"158398356","repostType":1,"repost":{"id":158398356,"gmtCreate":1625127750775,"gmtModify":1703736679400,"author":{"id":"3585222150655793","authorId":"3585222150655793","name":"Skyciti","avatar":"https://static.tigerbbs.com/f12b30dddbedf14f6cef0d78f22860c9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585222150655793","authorIdStr":"3585222150655793"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hold…..it will rocket soon.","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hold…..it will rocket soon.","text":"$CEL-SCI Corp(CVM)$Hold…..it will rocket soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158398356","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151618757,"gmtCreate":1625080937979,"gmtModify":1703735709577,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hi allgive opinion..i am new on this stock. Should i sell or hold?","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hi allgive opinion..i am new on this stock. Should i sell or hold?","text":"$CEL-SCI Corp(CVM)$Hi allgive opinion..i am new on this stock. Should i sell or hold?","images":[{"img":"https://static.tigerbbs.com/37e23442e9639e8f453bac2e6914f932","width":"1600","height":"2844"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":5,"repostSize":2,"link":"https://ttm.financial/post/151618757","isVote":1,"tweetType":1,"viewCount":1895,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":151613571,"gmtCreate":1625080326793,"gmtModify":1703735706954,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>what happened? Should i hold or sell?&nbsp;","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>what happened? Should i hold or sell?&nbsp;","text":"$CEL-SCI Corp(CVM)$what happened? Should i hold or sell?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151613571","isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102533358,"gmtCreate":1620223055174,"gmtModify":1704340414548,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CAN\">$Canaan Inc.(CAN)$</a>Not sure what canni do,hold or blood weeping!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CAN\">$Canaan Inc.(CAN)$</a>Not sure what canni do,hold or blood weeping!&nbsp;","text":"$Canaan Inc.(CAN)$Not sure what canni do,hold or blood weeping!","images":[{"img":"https://static.tigerbbs.com/f07653b53b4ed4c23f4fb9fe97e9ce2f","width":"1600","height":"2844"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/102533358","isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":378139372,"gmtCreate":1619008971696,"gmtModify":1704718208361,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Pls response to my comment","listText":"Pls response to my comment","text":"Pls response to my comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/378139372","repostId":"1193736432","repostType":4,"repost":{"id":"1193736432","kind":"news","pubTimestamp":1618966262,"share":"https://ttm.financial/m/news/1193736432?lang=&edition=fundamental","pubTime":"2021-04-21 08:51","market":"us","language":"en","title":"Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1193736432","media":"cnbc","summary":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.Apple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.Investors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.Here are some of the highlight announcements, but scroll down to see","content":"<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 08:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/20/apple-event-live-updates.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1193736432","content_text":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\nApple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.\nInvestors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.\nHere are some of the highlight announcements, but scroll down to see more.\n\nApple Card features for teens and families\nPodcast subscriptions\nAirTag lost item finder\nA purple iPhone 12\nA new Apple TV boxandremote\niMacs in seven colors with Apple’s M1 chip\nImproved iPad Pros with Apple’s M1 chip\n\nApple announces updated iPad Pros with chip from desktop computers\nApple said on Tuesday that it will release new high-end iPad Pros that use the company’s M1 chip, which is also used in its Mac computers. Previously, iPads used A-series chips, which are what powers the company’s iPhones. Apple says it is the most powerful tablet on the market.\nIt also includes an improved USB-C connector that will allow the iPad to connect to higher-resolution monitors and download images from a camera more quickly.\nThe 12.9-inch iPad Pro features an improved screen using an array of LEDs that is brighter and has better color resolution than previous displays using a technology called Mini-LED.\niPad ProSource: Apple Inc.\nThe iPad Pro will also have a 12-megapixel front-facing camera with an ultrawide lens that can automatically pan to keep human subjects in the shot.\nSome models will include 5G support, Apple said. The 11-inch model starts at $799, and the 12.9-inch model costs $1,099. They will be available for preorder on April 30 and will ship in late May.— Kif Leswing\niPad ProSource: Apple Inc.\nApple announces new iMac models that come in different colors\nApple launches new iMac.Source: Apple Inc.\nThese iMacs are powered by Apple's custom M1 silicon, not Intel processors. The computers have a new, thinner aluminum design, and they come in red, blue, purple, orange, yellow, silver, and green. The new thinner design looks a lot like a big iPad.\nApple launches new iMac with new colors.Source: Apple Inc.\nApple says the volume of the computer has been reduced by 50%, resulting in a smaller computer that can fit on a desk more easily. It comes with a 24-inch built-in display and an improved camera that can record 1080p video in low light. Apple says the display runs at \"4.5K\" resolution.\nIt ships with a new magnetic power connector reminiscent of Apple's previous MagSafe laptop chargers and a slightly updated keyboard with an emoji key and a fingerprint sensor. Apple's mouses and keyboard come in the same colors as the new iMacs.\nThe entry-level model costs $1,299, and an upgraded version costs $1,499. The new iMacs will go up for preorder on April 30 and will ship in the second half of May, Apple said.\nApple's first iMacs, released 20 years ago, also came in different colors.\nSource: Apple Inc.\nThe Apple TV finally has a brand-new remoteApple Inc.\nApple is finally rolling out a new, redesigned remote for the Apple TV. It's made of aluminum and has dedicated buttons for navigating menus, which should solve some of the headaches caused by the earlier remote. It will ship in the second half of May with the new Apple TV 4K, which costs $179 or $199 depending on the model.\n— Jessica Bursztynsky\nApple updates Apple TV 4K box with new processor\nApple announced that its Apple TV 4K box has been updated with a new processor, and it will be able to handle high frame rate HDR video which will result in displaying smoother, more colorful sports events.\nIt will also include a new feature that will use the iPhone's camera to tune the TV's picture quality.\nIt also comes with a completely redesigned remote made of aluminum with physical buttons, instead of the old remote’s touchpad. It can also control your TV’s power. Instead of a touchpad, it has a wheel for controlling the display.\nIt starts at $179 for 32GB of storage. It goes up for preorder on April 30 and will start shipping in the second half of May, Apple said.— Kif Leswing\nApple announces long-expected lost-item tracker called AirTag\n\nApple announced AirTag, calling it an iPhone accessory, priced at $29 for one or $99 for four. It will be on store shelves on April 30.\nIt uses Apple technology called Find My, which uses a network of iPhones to find lost objects. It’s using a technique Apple calls “precision finding” that it says is privacy-sensitive.\nThis product has been the source of some scrutiny from lawmakers who have heard that Apple is privileging its own lost-item trackers over others’ using anticompetitive practices and access to the iPhone operating system. Find My opened to third-party accessory makers last month.— Kif Leswing\nApple introduces new iPhone 12 color: Purple\nApple launches a new purple color iPhone for Spring.Source: Apple\nIt goes up for preorder on Friday and will ship on April 30.— Kif Leswing\nApple launching podcast subscription service\nApple announced that it’s launching its podcast subscription service next month, putting itself up further against Spotify and other competitors in the audio streaming wars.\nThe company is also redesigning its Apple Podcast app.\n— Jessica Bursztynsky\nApple says that credit scores are unfair, expands Apple Card to kids over 13 years old\nCEO Tim Cook said Apple will allow partners and spouses to share a credit line on a credit card, allowing both people to build credit scores. It’s also introducing features for families and teenagers. Apple was notably under fire fromco-founder Steve Wozniakafter people discovered that sometimes spouses had different credit limits.— Kif Leswing\nApple CEO Tim Cook kicks off the event\nTim Cook, CEO of Apple, speaks during an Apple Event on April 20th, 2021.Source: Apple Inc.\nWalking around Apple Park, Apple’s campus in Cupertino, California, Apple CEO Tim Cook kicked off the event with factoids about Apple’s environmental efforts, saying that Apple is carbon-neutral and hopes to remove 1 million tons of carbon from the environment per year.— Kif Leswing\nOver 360,000 people livestreaming Apple launch on YouTube\nAs Apple’s event kicks off, YouTube shows more than 360,000 people are streaming it on that platform. Apple’s three launch events last fall each garnered millions of people watching live on YouTube. It’s also available streaming directly on Apple’s website, which isn’t counted in the YouTube numbers.— Kif Leswing\nData point: iPads have been on a hot streak\nVarious models of the Apple Inc. iPad at the company’s Yeouido store during its opening in Seoul, South Korea, on Friday, Feb. 26, 2021.Jean Chung | Bloomberg | Getty Images\nAs Apple prepares to potentially release new iPads, remember that the product has had a great pandemic:In the fourth calendar quarter of 2020, Apple shipped $8.44 billion in iPads — which was up 41% year over year.— Kif Leswing\nApple’s spring events are typically more muted than its fall launch extravaganzas\nApple is best known for its fall launch events, where it reveals new iPhones, but it’s no stranger to hosting somewhat lower-profile events in the spring.\nApple didn’t hold a spring event in 2020 due to the onset of the coronavirus pandemic and instead launched new iPads and other gadgets on its website. In 2019, Apple’s spring announcement focused on services such asApple TV+and theApple Card. But it also announced new iPads in 2018 during an education-focused event at a school in Chicago.\nLast fall, Apple broadcast three prerecorded product launch events in three months, each of which garnered millions of live viewers on YouTube.— Kif Leswing\nYes, the Apple online store is down. No, it’s not a problem, it’s a tradition.\nScreenshot/Apple.com\nOne of Apple’s silliest traditions is that on the morning of an event it pulls its online Apple store down, giving up a few hours of online sales in exchange for building hype over its new products. Apple has done this for years, and technology has certainly gotten to the point where Apple could update its store without downtime — it does it all the time — but why mess with a tradition?— Kif Leswing\nWhat’s at stake for Apple?\nI wrote yesterday about some of thetensions bubbling under the surface at Apple. Yes, this is just another product event, but there are a lot of headaches on the horizon that could threaten its growth, especially in the App Store.\nThere’s the war of words withFacebookover theimpending iOS privacy feature. There’s the upcoming trial with Epic Games that centers on Apple’s control of the App Store. And then there’s Apple’s dependence on China, which is an obvious target for Apple critics. (Just ask Peter Thiel.)\nRead all about it right here.\n— Steve Kovach\nCook gets ready to kick off the event\nAppleCEO Tim Cook is gearing up for Tuesday’s “Spring Loaded” event, where the company is expected to announce new iPads and potentially a handful of other products. “It’s a beautiful spring morning for an #AppleEvent! See you soon,” Cook tweeted.\n— Jessica Bursztynsky","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378198954,"gmtCreate":1619008500378,"gmtModify":1704718198297,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Tell me more","listText":"Tell me more","text":"Tell me more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378198954","repostId":"2129871399","repostType":2,"repost":{"id":"2129871399","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619007453,"share":"https://ttm.financial/m/news/2129871399?lang=&edition=fundamental","pubTime":"2021-04-21 20:17","market":"us","language":"en","title":"BRIEF-Bit Digital Reports New 40MW Agreement With Compute North","url":"https://stock-news.laohu8.com/highlight/detail?id=2129871399","media":"Reuters","summary":"April 21 (Reuters) - Bit Digital Inc   :   * BIT DIGITAL EXPANDS NORTH AMERICAN FOOTPRINT WITH NEW 4","content":"<html><body><p>April 21 (Reuters) - Bit Digital Inc   :</p><p>   * BIT DIGITAL EXPANDS <a href=\"https://laohu8.com/S/NAIT.UK\">NORTH AMERICAN</a> FOOTPRINT WITH NEW 40MW AGREEMENT WITH COMPUTE NORTH</p><p>   * BIT DIGITAL INC - AS PART OF AGREEMENT, CO WILL DEPLOY AN ADDITIONAL 13,000 ASIC MINERS AT COMPUTE NORTH FACILITIES IN UNITED STATES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bit Digital Reports New 40MW Agreement With Compute North</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bit Digital Reports New 40MW Agreement With Compute North\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-21 20:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>April 21 (Reuters) - Bit Digital Inc   :</p><p>   * BIT DIGITAL EXPANDS <a href=\"https://laohu8.com/S/NAIT.UK\">NORTH AMERICAN</a> FOOTPRINT WITH NEW 40MW AGREEMENT WITH COMPUTE NORTH</p><p>   * BIT DIGITAL INC - AS PART OF AGREEMENT, CO WILL DEPLOY AN ADDITIONAL 13,000 ASIC MINERS AT COMPUTE NORTH FACILITIES IN UNITED STATES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DLR":"数字房地产信托公司","BTBT":"Bit Digital, Inc.","NGD":"New Gold"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129871399","content_text":"April 21 (Reuters) - Bit Digital Inc   :   * BIT DIGITAL EXPANDS NORTH AMERICAN FOOTPRINT WITH NEW 40MW AGREEMENT WITH COMPUTE NORTH   * BIT DIGITAL INC - AS PART OF AGREEMENT, CO WILL DEPLOY AN ADDITIONAL 13,000 ASIC MINERS AT COMPUTE NORTH FACILITIES IN UNITED STATESSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378193164,"gmtCreate":1619008382358,"gmtModify":1704718196358,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Tell me more","listText":"Tell me more","text":"Tell me more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378193164","repostId":"2129087941","repostType":4,"repost":{"id":"2129087941","kind":"highlight","pubTimestamp":1619006100,"share":"https://ttm.financial/m/news/2129087941?lang=&edition=fundamental","pubTime":"2021-04-21 19:55","market":"us","language":"en","title":"3 Stocks That Offer Explosive Potential Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2129087941","media":"Motley Fool","summary":"All of these companies have major catalysts ahead of them.","content":"<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.</p><p>These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.</p><p>Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker <b>NIO</b> (NYSE:NIO), EV charging network leader <b>ChargePoint Holdings</b> (NYSE:CHPT), and North American steelmaker <b>Nucor</b> (NYSE:NUE) could produce significant gains for shareholders in the years ahead.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fnioet7-hero-design.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"435\" referrerpolicy=\"no-referrer\"></p><p>The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.</p><h2>NIO: A massive and growing market</h2><p>As recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.</p><p>EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.</p><p>The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.</p><p>The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with<b> Ford</b> (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fchargepoint-ev-charging-for-multi-family1-copy.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: ChargePoint.</p><h2>ChargePoint: A network of vital infrastructure</h2><p>With more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.</p><p>It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.</p><p>President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.</p><p>Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. <b>General Motors</b> (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.</p><h2>Nucor: New records on the horizon</h2><p>Leading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"</p><p>There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be <a href=\"https://laohu8.com/S/AONE\">one</a> of the biggest beneficiaries of this as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top two low-cost steel producers in the U.S.</p><p>Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.</p><p>But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Offer Explosive Potential Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Offer Explosive Potential Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NUE":"纽柯钢铁"},"source_url":"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129087941","content_text":"Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker NIO (NYSE:NIO), EV charging network leader ChargePoint Holdings (NYSE:CHPT), and North American steelmaker Nucor (NYSE:NUE) could produce significant gains for shareholders in the years ahead.The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.NIO: A massive and growing marketAs recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with Ford (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.Image source: ChargePoint.ChargePoint: A network of vital infrastructureWith more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. General Motors (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.Nucor: New records on the horizonLeading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be one of the biggest beneficiaries of this as one of the top two low-cost steel producers in the U.S.Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378199690,"gmtCreate":1619008312910,"gmtModify":1704718195342,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"How?","listText":"How?","text":"How?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378199690","repostId":"1105485810","repostType":4,"repost":{"id":"1105485810","kind":"news","pubTimestamp":1619003862,"share":"https://ttm.financial/m/news/1105485810?lang=&edition=fundamental","pubTime":"2021-04-21 19:17","market":"fut","language":"en","title":"Three indirect ways investors can play the cryptocurrency craze","url":"https://stock-news.laohu8.com/highlight/detail?id=1105485810","media":"CNBC","summary":"The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo ha","content":"<div>\n<p>The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo has started letting users to buy, sell and hold bitcoin,ethereum,litecoin and bitcoin cash, the next ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three indirect ways investors can play the cryptocurrency craze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree indirect ways investors can play the cryptocurrency craze\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo has started letting users to buy, sell and hold bitcoin,ethereum,litecoin and bitcoin cash, the next ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1105485810","content_text":"The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo has started letting users to buy, sell and hold bitcoin,ethereum,litecoin and bitcoin cash, the next step in PayPal’s foray into digital assets.\nBut in some cases, investors might find more luck with indirect crypto plays than the currencies themselves, two traders told CNBC on Tuesday.\n“In this case — the rush to the mining — it’s better to sell the picks and shovels than necessarily go for the mined asset,” Chantico Global founder and CEO Gina Sanchez said on“Trading Nation.”\nPayPal, for one, will make “extraordinary fees” off Venmo’s move, said Sanchez, also chief market strategist at Lido Advisors.\n“We own PayPal in our portfolio [at Lido Advisors]. We also own other chip names like Nvidia and Intel,” she said. “You need two things to mine bitcoin: you need very powerful computers and you need electricity. Electricity’s harder to play, but the chip shortage is easier.”\nAs businesses embrace digital assets, companies that help facilitate crypto transactions could also win out, Strategic Wealth Partners president and CEO Mark Tepper said in the same interview.\n“Silvergate’sa bank ... that works with all the crypto companies out there. Venmo’s allowing its users to access crypto through Paxos, which happens to be a Silvergate customer. So Silvergate’s going to benefit from this whole Venmo deal,” Tepper said.\n“I really like them as a play and I think they’re actually going to benefit tremendously from what Venmo’s doing,” he said.\nAs for bitcoin itself, more hype will likely bring higher prices, Tepper said.\n“What’s really going to drive bitcoin higher is more and more adoption,” he said. “If Amazon ever were to all of a sudden accept payments in bitcoin, I think bitcoin would shoot to over 100,000 overnight. So, yes, the more you see companies adopt and embrace it, I think the higher bitcoin goes.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378190715,"gmtCreate":1619008261937,"gmtModify":1704718195019,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Say it again","listText":"Say it again","text":"Say it again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378190715","repostId":"1140867286","repostType":4,"repost":{"id":"1140867286","kind":"news","pubTimestamp":1619004558,"share":"https://ttm.financial/m/news/1140867286?lang=&edition=fundamental","pubTime":"2021-04-21 19:29","market":"us","language":"en","title":"Should You Buy Peloton Stock: What To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=1140867286","media":"seekingalpha","summary":"Summary\n\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of dema","content":"<p><b>Summary</b></p>\n<ul>\n <li>Peloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues.</li>\n <li>Peloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021, which beat market expectations, but its slowing revenue growth momentum led to its share price declining post-results.</li>\n <li>I like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors.</li>\n <li>But Peloton is not as attractive as an investment due to its rather rich valuations.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8b9a7cebe129367e4549d92aecef0d75\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Maridav/iStock via Getty Images</span></p>\n<p><b>Elevator Pitch</b></p>\n<p>I assign a Neutral rating to Peloton Interactive, Inc.(NASDAQ:PTON).</p>\n<p>Peloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues. Peloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021 (YE June 30) which beat market expectations, but its slowing revenue growth momentum (versus +232% YoY revenue growth in 1Q FY 2021) led to its share price declining by -6% post-results.</p>\n<p>I like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors. Furthermore, Peloton is not as attractive as an investment due to its rather rich valuations. Peloton trades at consensus forward FY 2021 Enterprise Value-to-Revenue and EV/EBITDA multiples of 7.3 times and 91.8 times. These numbers will be more reasonable if PTON is a SaaS (Software-as-a-Service) company, but Peloton still derives over 80% of its revenue from product sales as opposed to digital subscriptions. As a result, I see Peloton Interactive, Inc's shares as a HOLD.</p>\n<p><b>Company Description</b></p>\n<p>Established in 2012 and listed on the NASDAQ in&nbsp;September 2020, Peloton Interactive, Inc.calls itself&nbsp;\"the largest interactive fitness platform in the world\" in the company's 2Q FY 2021 10-Q. Peloton has&nbsp;over 4.4 million members&nbsp;as of end-2020 (calendar year), and \"any individual who has a Peloton account through a paid Connected Fitness subscription, or a paid Peloton Digital subscription\" is&nbsp;counted as&nbsp;a member.</p>\n<p>PTON derived&nbsp;81% and 19%&nbsp;of its 1H FY 2021 revenue from Connected Fitness product sales (e.g. its Bike and Tread products) and subscription fees (for both Connected Fitness and Peloton Digital subscriptions), respectively. With regards to earnings contribution, the Connected Fitness products and the subscription business accounted for 72% and 18% of Peloton's top line in the first half of fiscal 2021. In terms of geographical sales mix, Peloton generated 95% of the company's 1H FY 2021 sales from North America, with other international markets contributing the remaining 5% of its revenue over the same period.</p>\n<p><b>Why Did Peloton Stock Drop?</b></p>\n<p>2020 was a great year for Peloton Interactive, Inc in terms of stock price performance, as the company's share price surged by +434% from $28.40 as of December 31, 2019 to $151.72 as of December 31, 2020. The same can't be said of 2021, as PTON's last traded price of $107.75 as of April 19, 2021 represents a year-to-date decline of -29%.</p>\n<p>Peloton's stock price has dropped significantly in 2021 year-to-date for a number of reasons.</p>\n<p>Firstly, investors are concerned that Work-From-Home or WFH tailwinds for Peloton will ease once the coronavirus pandemic wanes. Peloton has been a key beneficiary of an increasing number of people working and exercising at home due to COVID-19, but there is no certainty that such trends will persist post-pandemic. Based on&nbsp;data&nbsp;from&nbsp;<i>Bloomberg's COVID Vaccine Tracker</i>, 25.7% of the US population has already been fully vaccinated, while 39.9% of the people in the country have at least been administrated a single dose of the COVID-19 vaccine.</p>\n<p>In other words, the market is worried about more people returning to offices and exercising at gyms again and its impact on PTON's future performance. In response, Peloton&nbsp;stressed&nbsp;at the JMP Securities Technology Conference on March 1, 2021 that exercising at home \"is a trend that's here to stay\" and \"COVID just accelerated that trend.\" The company also added that \"people have found a way not only to replicate exercising outside of the home, but enjoy it more and perhaps are doing even more than they were even pre-pandemic\", based on its analysis of members' data.</p>\n<p>Nevertheless, it remains a significant unknown as to how consumers' behaviors will change and evolve post-pandemic.</p>\n<p>Secondly, Peloton has faced challenges in converting all of the consumer demand for its Connected Fitness products into actual sales.</p>\n<p>At the company's 2Q FY 2021 results briefing on February 4, 2021, Peloton&nbsp;acknowledged&nbsp;that \"our delivery wait times remain elevated.\" It also highlighted that \"West Coast port delays and COVID-related delivery challenges\" resulted in longer-than-expected \"order to delivery wait times\" and \"forced us to reschedule many deliveries.\"</p>\n<p>But Peloton is actively trying to address these issues. On April 1, 2021, Peloton disclosed that it had completed the acquisition of&nbsp;Precor, which it&nbsp;refers to&nbsp;as&nbsp;\"one of the largest global commercial fitness equipment providers with a significant U.S. manufacturing presence.\" This should help to ease Peloton's production capacity issues. Also, Peloton has also committed to an additional investment of&nbsp;$100 million&nbsp;with the aim of restoring delivery wait times to normalized levels by end of FY 2021 (June 30, 2022) at the latest.</p>\n<p>The key concerns here are that this could result in significant customer dissatisfaction and also lead investors to turn to other alternative options such as going back to the gyms (if possible) or buying other competing home fitness products.</p>\n<p>Thirdly, Peloton's stock price has been affected by product safety issues raised by the Consumer Product Safety Commission or CPSC.</p>\n<p>The CSPC published a&nbsp;press release&nbsp;on April 17, 2021 \"warning consumers about the danger of popular Peloton Tread+ exercise machine after multiple incidents of small children and a pet being injured beneath the machines.\" Peloton has responded with a&nbsp;media release&nbsp;of its own on the same day, stating that the CSPC press release is \"inaccurate and misleading\". The company also emphasized that \"there is no reason to stop using the Tread+, as long as all warnings and safety instructions are followed.\"</p>\n<p>Peloton's share price fell by -7% from $116.21 as of April 16, 2021 to $107.75 as of April 19, 2021 following CSPC's press release and Peloton's response. The company has an incredible brand and a strong following as evidenced by some of its fans having Peloton&nbsp;tattoos, so it might take more than a warning from the CSPC to hurt its future sales. However, it is worth following the developments relating to this matter on product safety issues to evaluate any potential damage to Peloton's brand.</p>\n<p>In a nutshell, the most important issue for long-term investors in Peloton is how consumers' attitudes towards home fitness &amp; exercise will change post-COVID, which will affect the company's future growth runway. On the other hand, product delivery bottlenecks should be resolved in time to come, while the product safety concerns could blow over soon as well.</p>\n<p><b>How Is Peloton Doing Financially?</b></p>\n<p>Peloton Interactive, Inc reported its most recent&nbsp;2Q FY 2021 financial results&nbsp;(October 1, 2020 to December 31, 2020 period) on February 4, 2021. The company's financial performance in the second quarter of the current fiscal year was above market expectations.</p>\n<p>PTON's revenue rose by +128% YoY from $466 million in 2Q FY 2020 to $1,065 million in 2Q FY 2021, which was approximately&nbsp;+3% better&nbsp;that what Wall Street had expected. This was driven by a +124% YoY increase in Connected Fitness product sales and a +153% YoY growth in subscription revenue. The company also reversed from a net loss per share of -$0.20 in 2Q FY 2020 to a positive earnings per share of $0.18 in 2Q FY 2021. This was more than double the sell-side analysts' quarterly consensus earnings estimate of&nbsp;$0.08 per share.</p>\n<p>However, Peloton's share price declined by -6% from $157.53 as of February 4, 2021 to $148.30 as of February 5, 2021 post-results. The company's stock price subsequently dropped to a year-to-date low of $101.35 on March 8, 2021. This suggests that Peloton's financial performance might not be as good as what it appears on paper, if one delves deeper.</p>\n<p>Notably, Peloton's YoY revenue growth narrowed significantly from +232% YoY in 1Q FY 2021 and +172% YoY in 4Q FY 2020 to +128% in 2Q FY 2021. PTON is guiding for&nbsp;$1.10 billion&nbsp;in revenue for 3Q FY 2021, which translates to a top line growth of +110% YoY in the next quarter. This could be attributable to both product delivery issues and demand normalization (highlighted earlier), but there is no escaping the fact that Peloton's revenue growth is slowing.</p>\n<p>In terms of operating metrics, it is noteworthy that the average workouts per month per subscribers for PTON has stabilized at&nbsp;20.7 and 21.1&nbsp;for 1Q FY 2021 and 2Q FY 2021 respectively. In comparison, Peloton's average workouts per month per subscribers jumped from 17.7 in 3Q FY 2020 to 24.7 in 4Q FY 2020. This could be another sign that home fitness demand is starting to normalize.</p>\n<p><b>PTON Stock Analysis</b></p>\n<p>There are a number of things that investors should like about Peloton Interactive, Inc as a business.</p>\n<p>One key characteristic of PTON's business is that the company has an amazing brand. As I indicated earlier, some of Peloton's followers even have the brand's logo tattooed on their bodies, which is the clearest indication of Peloton's brand equity. Also, consulting firm<i>Prophet</i>namedPeloton as the second most relevant brand in the US in 2021 based ona survey of approximately 13,000 consumers. Peloton only ranked behind Apple(NASDAQ:AAPL), and it beat other household brands like Lego, Costco(NASDAQ:COST)and Amazon(NASDAQ:AMZN). Prophet's studyhighlightsthat PTON \"earns the highest score for 'connects with me emotionally' via \"its online communities and its constantly expanding variety of workouts available live and prerecorded.\"</p>\n<p>Another key characteristic of Peloton's business is that it offers a compelling value proposition for consumers. A Connected Fitness subscription costs $39 per month, and the company's Connected Fitness products like bikes are priced at around a few thousand dollars ($1,895for flagship bike product) which can be paid in installments and used by all the people living together. In other words, the all-in cost of working out at home by using PTON's products and services are much cheaper than an annual individual gym membership subscription. In addition, an April 9, 2021<i>Wall Street Journal</i>articlecited Credit Suisse sell-side research which suggested that \"the monthly cost\" of \"a Peloton bike with a digital membership\" for a couple is \"87% below the cost\" of \"10 SoulCycle classes a month.\" Notably, Peloton's Average Net Monthly Connected Fitness Churncalculated as\"cancellations, net of reactivations\" divided by the number of Connected Fitness subscriptions was below 1% for both FY 2020 and FY 2019.</p>\n<p>Moving forward, Peloton has a long growth runway ahead, considering its multiple growth drivers.</p>\n<p>One growth driver is new products and cross-selling. It is telling that only3%of Peloton's Connected Fitness' subscribers have both Bike and Tread products from the company. PTONobservedat the recent earnings call that there has been a \"continued mix shift to (the new) Tread products\" andmentionedat the JMP Securities Technology Conference that \"two-product households\" are \"more engaged than people who had have 1 piece of equipment.\" Looking ahead, it is likely that Peloton can increase the proportion of its subscribers who have bought both the Bike and Tread products, and such \"two-product households\" could also be interested in more fitness courses and programs offered by the company leading to higher subscription revenue as well.</p>\n<p>Another key growth driver is potential synergies associated with the acquisition of Precor highlighted above. Although Peloton has a significant US consumer presence, it is not as strong in commercial and international markets, and Precor could help to fill in the gap. In the company's earlier press release announcing the Precor acquisition, Pelotonnotednew growth opportunities in channels like \"hotels, multifamily residences, and college and corporate campuses.\" Also, while Peloton generated 95% of its 1H FY 2021 revenue from North America as highlighted earlier, Precor hasa presencein \"90 countries around the world.\" PTON has already expanded into the UK and Canada, but there is a lot of room for further overseas expansion.</p>\n<p>On the flip side, the huge growth potential of the home fitness market inevitably attracts competition. One key competitor isMirrorreferred to as an \"interactive smart gym\" enabled by \"advanced camera technology and machine learning\", The Mirror is , which Lululemon(NASDAQ:LULU)acquired inmid-2020. Another one of Peloton's key competitors isTonal, which calls itself \"an all-in-one machine\" combining \"fitness and strength training with patented digital weight, machine learning, and expert coaching.\" Tonal has raised$450 millionin cumulative funding since its launch, and one of its notable investors include Amazon’s Alexa Fund.</p>\n<p>While I acknowledge that Peloton has a strong brand, the competitive landscape in the home fitness industry is still relatively unsettled. The market is growing, and one can't rule out more new entrants. More importantly, customer switching costs (i.e. a few thousand dollars for the Connected Fitness products) might not be sufficient to prevent consumers from switching to new products and other alternatives.</p>\n<p><b>Should You Buy Peloton Stock?</b></p>\n<p>I see Peloton stock as a HOLD, rather than a BUY. While Peloton is a good company, it is not a good investment as it stands now. PTON's valuations are rather rich, considering that the company still generates more than 80% of its sales from products, rather than digital subscriptions.</p>\n<p>The market values Peloton at 7.3 times consensus forward FY 2021 Enterprise Value-to-Revenue and 5.3 times consensus forward FY 2022 Enterprise Value-to-Revenue. The stock also trades at consensus forward FY 2021 and FY 2022 EV/EBITDA multiples of 91.8 times and 50.9 times, respectively.</p>\n<p>None of Peloton's direct peers are listed on a stand-alone basis, which makes peer valuation comparison challenging. PTON is much more expensive than its fitness peers based on forward EV/EBITDA multiples, although there is a significant divergence in Enterprise Value-to-Revenue ratios for the peer group.</p>\n<p><b>Peloton's Peer Valuation Comparison</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6f8be3d26f74a213f2aad2297c197307\" tg-width=\"904\" tg-height=\"605\"><span>Source: Author</span></p>\n<p>I have sourced the consensus numbers referenced in this article from S&amp;P Capital IQ.</p>\n<p>Peloton's key risk factors are a more significant normalization of home fitness demand post-COVID than earlier anticipated, further negative news flow relating to product safety issues, and stiffer-than-expected competition from rivals in the home fitness industry.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Peloton Stock: What To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Peloton Stock: What To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4420041-should-you-buy-peloton-stock-what-to-consider><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues.\nPeloton's revenue jumped by +...</p>\n\n<a href=\"https://seekingalpha.com/article/4420041-should-you-buy-peloton-stock-what-to-consider\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PTON":"Peloton Interactive, Inc."},"source_url":"https://seekingalpha.com/article/4420041-should-you-buy-peloton-stock-what-to-consider","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140867286","content_text":"Summary\n\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues.\nPeloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021, which beat market expectations, but its slowing revenue growth momentum led to its share price declining post-results.\nI like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors.\nBut Peloton is not as attractive as an investment due to its rather rich valuations.\n\nPhoto by Maridav/iStock via Getty Images\nElevator Pitch\nI assign a Neutral rating to Peloton Interactive, Inc.(NASDAQ:PTON).\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues. Peloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021 (YE June 30) which beat market expectations, but its slowing revenue growth momentum (versus +232% YoY revenue growth in 1Q FY 2021) led to its share price declining by -6% post-results.\nI like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors. Furthermore, Peloton is not as attractive as an investment due to its rather rich valuations. Peloton trades at consensus forward FY 2021 Enterprise Value-to-Revenue and EV/EBITDA multiples of 7.3 times and 91.8 times. These numbers will be more reasonable if PTON is a SaaS (Software-as-a-Service) company, but Peloton still derives over 80% of its revenue from product sales as opposed to digital subscriptions. As a result, I see Peloton Interactive, Inc's shares as a HOLD.\nCompany Description\nEstablished in 2012 and listed on the NASDAQ in September 2020, Peloton Interactive, Inc.calls itself \"the largest interactive fitness platform in the world\" in the company's 2Q FY 2021 10-Q. Peloton has over 4.4 million members as of end-2020 (calendar year), and \"any individual who has a Peloton account through a paid Connected Fitness subscription, or a paid Peloton Digital subscription\" is counted as a member.\nPTON derived 81% and 19% of its 1H FY 2021 revenue from Connected Fitness product sales (e.g. its Bike and Tread products) and subscription fees (for both Connected Fitness and Peloton Digital subscriptions), respectively. With regards to earnings contribution, the Connected Fitness products and the subscription business accounted for 72% and 18% of Peloton's top line in the first half of fiscal 2021. In terms of geographical sales mix, Peloton generated 95% of the company's 1H FY 2021 sales from North America, with other international markets contributing the remaining 5% of its revenue over the same period.\nWhy Did Peloton Stock Drop?\n2020 was a great year for Peloton Interactive, Inc in terms of stock price performance, as the company's share price surged by +434% from $28.40 as of December 31, 2019 to $151.72 as of December 31, 2020. The same can't be said of 2021, as PTON's last traded price of $107.75 as of April 19, 2021 represents a year-to-date decline of -29%.\nPeloton's stock price has dropped significantly in 2021 year-to-date for a number of reasons.\nFirstly, investors are concerned that Work-From-Home or WFH tailwinds for Peloton will ease once the coronavirus pandemic wanes. Peloton has been a key beneficiary of an increasing number of people working and exercising at home due to COVID-19, but there is no certainty that such trends will persist post-pandemic. Based on data from Bloomberg's COVID Vaccine Tracker, 25.7% of the US population has already been fully vaccinated, while 39.9% of the people in the country have at least been administrated a single dose of the COVID-19 vaccine.\nIn other words, the market is worried about more people returning to offices and exercising at gyms again and its impact on PTON's future performance. In response, Peloton stressed at the JMP Securities Technology Conference on March 1, 2021 that exercising at home \"is a trend that's here to stay\" and \"COVID just accelerated that trend.\" The company also added that \"people have found a way not only to replicate exercising outside of the home, but enjoy it more and perhaps are doing even more than they were even pre-pandemic\", based on its analysis of members' data.\nNevertheless, it remains a significant unknown as to how consumers' behaviors will change and evolve post-pandemic.\nSecondly, Peloton has faced challenges in converting all of the consumer demand for its Connected Fitness products into actual sales.\nAt the company's 2Q FY 2021 results briefing on February 4, 2021, Peloton acknowledged that \"our delivery wait times remain elevated.\" It also highlighted that \"West Coast port delays and COVID-related delivery challenges\" resulted in longer-than-expected \"order to delivery wait times\" and \"forced us to reschedule many deliveries.\"\nBut Peloton is actively trying to address these issues. On April 1, 2021, Peloton disclosed that it had completed the acquisition of Precor, which it refers to as \"one of the largest global commercial fitness equipment providers with a significant U.S. manufacturing presence.\" This should help to ease Peloton's production capacity issues. Also, Peloton has also committed to an additional investment of $100 million with the aim of restoring delivery wait times to normalized levels by end of FY 2021 (June 30, 2022) at the latest.\nThe key concerns here are that this could result in significant customer dissatisfaction and also lead investors to turn to other alternative options such as going back to the gyms (if possible) or buying other competing home fitness products.\nThirdly, Peloton's stock price has been affected by product safety issues raised by the Consumer Product Safety Commission or CPSC.\nThe CSPC published a press release on April 17, 2021 \"warning consumers about the danger of popular Peloton Tread+ exercise machine after multiple incidents of small children and a pet being injured beneath the machines.\" Peloton has responded with a media release of its own on the same day, stating that the CSPC press release is \"inaccurate and misleading\". The company also emphasized that \"there is no reason to stop using the Tread+, as long as all warnings and safety instructions are followed.\"\nPeloton's share price fell by -7% from $116.21 as of April 16, 2021 to $107.75 as of April 19, 2021 following CSPC's press release and Peloton's response. The company has an incredible brand and a strong following as evidenced by some of its fans having Peloton tattoos, so it might take more than a warning from the CSPC to hurt its future sales. However, it is worth following the developments relating to this matter on product safety issues to evaluate any potential damage to Peloton's brand.\nIn a nutshell, the most important issue for long-term investors in Peloton is how consumers' attitudes towards home fitness & exercise will change post-COVID, which will affect the company's future growth runway. On the other hand, product delivery bottlenecks should be resolved in time to come, while the product safety concerns could blow over soon as well.\nHow Is Peloton Doing Financially?\nPeloton Interactive, Inc reported its most recent 2Q FY 2021 financial results (October 1, 2020 to December 31, 2020 period) on February 4, 2021. The company's financial performance in the second quarter of the current fiscal year was above market expectations.\nPTON's revenue rose by +128% YoY from $466 million in 2Q FY 2020 to $1,065 million in 2Q FY 2021, which was approximately +3% better that what Wall Street had expected. This was driven by a +124% YoY increase in Connected Fitness product sales and a +153% YoY growth in subscription revenue. The company also reversed from a net loss per share of -$0.20 in 2Q FY 2020 to a positive earnings per share of $0.18 in 2Q FY 2021. This was more than double the sell-side analysts' quarterly consensus earnings estimate of $0.08 per share.\nHowever, Peloton's share price declined by -6% from $157.53 as of February 4, 2021 to $148.30 as of February 5, 2021 post-results. The company's stock price subsequently dropped to a year-to-date low of $101.35 on March 8, 2021. This suggests that Peloton's financial performance might not be as good as what it appears on paper, if one delves deeper.\nNotably, Peloton's YoY revenue growth narrowed significantly from +232% YoY in 1Q FY 2021 and +172% YoY in 4Q FY 2020 to +128% in 2Q FY 2021. PTON is guiding for $1.10 billion in revenue for 3Q FY 2021, which translates to a top line growth of +110% YoY in the next quarter. This could be attributable to both product delivery issues and demand normalization (highlighted earlier), but there is no escaping the fact that Peloton's revenue growth is slowing.\nIn terms of operating metrics, it is noteworthy that the average workouts per month per subscribers for PTON has stabilized at 20.7 and 21.1 for 1Q FY 2021 and 2Q FY 2021 respectively. In comparison, Peloton's average workouts per month per subscribers jumped from 17.7 in 3Q FY 2020 to 24.7 in 4Q FY 2020. This could be another sign that home fitness demand is starting to normalize.\nPTON Stock Analysis\nThere are a number of things that investors should like about Peloton Interactive, Inc as a business.\nOne key characteristic of PTON's business is that the company has an amazing brand. As I indicated earlier, some of Peloton's followers even have the brand's logo tattooed on their bodies, which is the clearest indication of Peloton's brand equity. Also, consulting firmProphetnamedPeloton as the second most relevant brand in the US in 2021 based ona survey of approximately 13,000 consumers. Peloton only ranked behind Apple(NASDAQ:AAPL), and it beat other household brands like Lego, Costco(NASDAQ:COST)and Amazon(NASDAQ:AMZN). Prophet's studyhighlightsthat PTON \"earns the highest score for 'connects with me emotionally' via \"its online communities and its constantly expanding variety of workouts available live and prerecorded.\"\nAnother key characteristic of Peloton's business is that it offers a compelling value proposition for consumers. A Connected Fitness subscription costs $39 per month, and the company's Connected Fitness products like bikes are priced at around a few thousand dollars ($1,895for flagship bike product) which can be paid in installments and used by all the people living together. In other words, the all-in cost of working out at home by using PTON's products and services are much cheaper than an annual individual gym membership subscription. In addition, an April 9, 2021Wall Street Journalarticlecited Credit Suisse sell-side research which suggested that \"the monthly cost\" of \"a Peloton bike with a digital membership\" for a couple is \"87% below the cost\" of \"10 SoulCycle classes a month.\" Notably, Peloton's Average Net Monthly Connected Fitness Churncalculated as\"cancellations, net of reactivations\" divided by the number of Connected Fitness subscriptions was below 1% for both FY 2020 and FY 2019.\nMoving forward, Peloton has a long growth runway ahead, considering its multiple growth drivers.\nOne growth driver is new products and cross-selling. It is telling that only3%of Peloton's Connected Fitness' subscribers have both Bike and Tread products from the company. PTONobservedat the recent earnings call that there has been a \"continued mix shift to (the new) Tread products\" andmentionedat the JMP Securities Technology Conference that \"two-product households\" are \"more engaged than people who had have 1 piece of equipment.\" Looking ahead, it is likely that Peloton can increase the proportion of its subscribers who have bought both the Bike and Tread products, and such \"two-product households\" could also be interested in more fitness courses and programs offered by the company leading to higher subscription revenue as well.\nAnother key growth driver is potential synergies associated with the acquisition of Precor highlighted above. Although Peloton has a significant US consumer presence, it is not as strong in commercial and international markets, and Precor could help to fill in the gap. In the company's earlier press release announcing the Precor acquisition, Pelotonnotednew growth opportunities in channels like \"hotels, multifamily residences, and college and corporate campuses.\" Also, while Peloton generated 95% of its 1H FY 2021 revenue from North America as highlighted earlier, Precor hasa presencein \"90 countries around the world.\" PTON has already expanded into the UK and Canada, but there is a lot of room for further overseas expansion.\nOn the flip side, the huge growth potential of the home fitness market inevitably attracts competition. One key competitor isMirrorreferred to as an \"interactive smart gym\" enabled by \"advanced camera technology and machine learning\", The Mirror is , which Lululemon(NASDAQ:LULU)acquired inmid-2020. Another one of Peloton's key competitors isTonal, which calls itself \"an all-in-one machine\" combining \"fitness and strength training with patented digital weight, machine learning, and expert coaching.\" Tonal has raised$450 millionin cumulative funding since its launch, and one of its notable investors include Amazon’s Alexa Fund.\nWhile I acknowledge that Peloton has a strong brand, the competitive landscape in the home fitness industry is still relatively unsettled. The market is growing, and one can't rule out more new entrants. More importantly, customer switching costs (i.e. a few thousand dollars for the Connected Fitness products) might not be sufficient to prevent consumers from switching to new products and other alternatives.\nShould You Buy Peloton Stock?\nI see Peloton stock as a HOLD, rather than a BUY. While Peloton is a good company, it is not a good investment as it stands now. PTON's valuations are rather rich, considering that the company still generates more than 80% of its sales from products, rather than digital subscriptions.\nThe market values Peloton at 7.3 times consensus forward FY 2021 Enterprise Value-to-Revenue and 5.3 times consensus forward FY 2022 Enterprise Value-to-Revenue. The stock also trades at consensus forward FY 2021 and FY 2022 EV/EBITDA multiples of 91.8 times and 50.9 times, respectively.\nNone of Peloton's direct peers are listed on a stand-alone basis, which makes peer valuation comparison challenging. PTON is much more expensive than its fitness peers based on forward EV/EBITDA multiples, although there is a significant divergence in Enterprise Value-to-Revenue ratios for the peer group.\nPeloton's Peer Valuation Comparison\nSource: Author\nI have sourced the consensus numbers referenced in this article from S&P Capital IQ.\nPeloton's key risk factors are a more significant normalization of home fitness demand post-COVID than earlier anticipated, further negative news flow relating to product safety issues, and stiffer-than-expected competition from rivals in the home fitness industry.","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378190947,"gmtCreate":1619008204589,"gmtModify":1704718193406,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Love this","listText":"Love this","text":"Love this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378190947","repostId":"2129087941","repostType":4,"repost":{"id":"2129087941","kind":"highlight","pubTimestamp":1619006100,"share":"https://ttm.financial/m/news/2129087941?lang=&edition=fundamental","pubTime":"2021-04-21 19:55","market":"us","language":"en","title":"3 Stocks That Offer Explosive Potential Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2129087941","media":"Motley Fool","summary":"All of these companies have major catalysts ahead of them.","content":"<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.</p><p>These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.</p><p>Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker <b>NIO</b> (NYSE:NIO), EV charging network leader <b>ChargePoint Holdings</b> (NYSE:CHPT), and North American steelmaker <b>Nucor</b> (NYSE:NUE) could produce significant gains for shareholders in the years ahead.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fnioet7-hero-design.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"435\" referrerpolicy=\"no-referrer\"></p><p>The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.</p><h2>NIO: A massive and growing market</h2><p>As recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.</p><p>EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.</p><p>The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.</p><p>The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with<b> Ford</b> (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fchargepoint-ev-charging-for-multi-family1-copy.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: ChargePoint.</p><h2>ChargePoint: A network of vital infrastructure</h2><p>With more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.</p><p>It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.</p><p>President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.</p><p>Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. <b>General Motors</b> (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.</p><h2>Nucor: New records on the horizon</h2><p>Leading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"</p><p>There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be <a href=\"https://laohu8.com/S/AONE\">one</a> of the biggest beneficiaries of this as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top two low-cost steel producers in the U.S.</p><p>Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.</p><p>But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Offer Explosive Potential Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Offer Explosive Potential Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NUE":"纽柯钢铁"},"source_url":"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129087941","content_text":"Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker NIO (NYSE:NIO), EV charging network leader ChargePoint Holdings (NYSE:CHPT), and North American steelmaker Nucor (NYSE:NUE) could produce significant gains for shareholders in the years ahead.The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.NIO: A massive and growing marketAs recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with Ford (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.Image source: ChargePoint.ChargePoint: A network of vital infrastructureWith more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. General Motors (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.Nucor: New records on the horizonLeading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be one of the biggest beneficiaries of this as one of the top two low-cost steel producers in the U.S.Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378107504,"gmtCreate":1619008153908,"gmtModify":1704718192748,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/378107504","repostId":"1193736432","repostType":4,"repost":{"id":"1193736432","kind":"news","pubTimestamp":1618966262,"share":"https://ttm.financial/m/news/1193736432?lang=&edition=fundamental","pubTime":"2021-04-21 08:51","market":"us","language":"en","title":"Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1193736432","media":"cnbc","summary":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.Apple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.Investors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.Here are some of the highlight announcements, but scroll down to see","content":"<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 08:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/20/apple-event-live-updates.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1193736432","content_text":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\nApple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.\nInvestors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.\nHere are some of the highlight announcements, but scroll down to see more.\n\nApple Card features for teens and families\nPodcast subscriptions\nAirTag lost item finder\nA purple iPhone 12\nA new Apple TV boxandremote\niMacs in seven colors with Apple’s M1 chip\nImproved iPad Pros with Apple’s M1 chip\n\nApple announces updated iPad Pros with chip from desktop computers\nApple said on Tuesday that it will release new high-end iPad Pros that use the company’s M1 chip, which is also used in its Mac computers. Previously, iPads used A-series chips, which are what powers the company’s iPhones. Apple says it is the most powerful tablet on the market.\nIt also includes an improved USB-C connector that will allow the iPad to connect to higher-resolution monitors and download images from a camera more quickly.\nThe 12.9-inch iPad Pro features an improved screen using an array of LEDs that is brighter and has better color resolution than previous displays using a technology called Mini-LED.\niPad ProSource: Apple Inc.\nThe iPad Pro will also have a 12-megapixel front-facing camera with an ultrawide lens that can automatically pan to keep human subjects in the shot.\nSome models will include 5G support, Apple said. The 11-inch model starts at $799, and the 12.9-inch model costs $1,099. They will be available for preorder on April 30 and will ship in late May.— Kif Leswing\niPad ProSource: Apple Inc.\nApple announces new iMac models that come in different colors\nApple launches new iMac.Source: Apple Inc.\nThese iMacs are powered by Apple's custom M1 silicon, not Intel processors. The computers have a new, thinner aluminum design, and they come in red, blue, purple, orange, yellow, silver, and green. The new thinner design looks a lot like a big iPad.\nApple launches new iMac with new colors.Source: Apple Inc.\nApple says the volume of the computer has been reduced by 50%, resulting in a smaller computer that can fit on a desk more easily. It comes with a 24-inch built-in display and an improved camera that can record 1080p video in low light. Apple says the display runs at \"4.5K\" resolution.\nIt ships with a new magnetic power connector reminiscent of Apple's previous MagSafe laptop chargers and a slightly updated keyboard with an emoji key and a fingerprint sensor. Apple's mouses and keyboard come in the same colors as the new iMacs.\nThe entry-level model costs $1,299, and an upgraded version costs $1,499. The new iMacs will go up for preorder on April 30 and will ship in the second half of May, Apple said.\nApple's first iMacs, released 20 years ago, also came in different colors.\nSource: Apple Inc.\nThe Apple TV finally has a brand-new remoteApple Inc.\nApple is finally rolling out a new, redesigned remote for the Apple TV. It's made of aluminum and has dedicated buttons for navigating menus, which should solve some of the headaches caused by the earlier remote. It will ship in the second half of May with the new Apple TV 4K, which costs $179 or $199 depending on the model.\n— Jessica Bursztynsky\nApple updates Apple TV 4K box with new processor\nApple announced that its Apple TV 4K box has been updated with a new processor, and it will be able to handle high frame rate HDR video which will result in displaying smoother, more colorful sports events.\nIt will also include a new feature that will use the iPhone's camera to tune the TV's picture quality.\nIt also comes with a completely redesigned remote made of aluminum with physical buttons, instead of the old remote’s touchpad. It can also control your TV’s power. Instead of a touchpad, it has a wheel for controlling the display.\nIt starts at $179 for 32GB of storage. It goes up for preorder on April 30 and will start shipping in the second half of May, Apple said.— Kif Leswing\nApple announces long-expected lost-item tracker called AirTag\n\nApple announced AirTag, calling it an iPhone accessory, priced at $29 for one or $99 for four. It will be on store shelves on April 30.\nIt uses Apple technology called Find My, which uses a network of iPhones to find lost objects. It’s using a technique Apple calls “precision finding” that it says is privacy-sensitive.\nThis product has been the source of some scrutiny from lawmakers who have heard that Apple is privileging its own lost-item trackers over others’ using anticompetitive practices and access to the iPhone operating system. Find My opened to third-party accessory makers last month.— Kif Leswing\nApple introduces new iPhone 12 color: Purple\nApple launches a new purple color iPhone for Spring.Source: Apple\nIt goes up for preorder on Friday and will ship on April 30.— Kif Leswing\nApple launching podcast subscription service\nApple announced that it’s launching its podcast subscription service next month, putting itself up further against Spotify and other competitors in the audio streaming wars.\nThe company is also redesigning its Apple Podcast app.\n— Jessica Bursztynsky\nApple says that credit scores are unfair, expands Apple Card to kids over 13 years old\nCEO Tim Cook said Apple will allow partners and spouses to share a credit line on a credit card, allowing both people to build credit scores. It’s also introducing features for families and teenagers. Apple was notably under fire fromco-founder Steve Wozniakafter people discovered that sometimes spouses had different credit limits.— Kif Leswing\nApple CEO Tim Cook kicks off the event\nTim Cook, CEO of Apple, speaks during an Apple Event on April 20th, 2021.Source: Apple Inc.\nWalking around Apple Park, Apple’s campus in Cupertino, California, Apple CEO Tim Cook kicked off the event with factoids about Apple’s environmental efforts, saying that Apple is carbon-neutral and hopes to remove 1 million tons of carbon from the environment per year.— Kif Leswing\nOver 360,000 people livestreaming Apple launch on YouTube\nAs Apple’s event kicks off, YouTube shows more than 360,000 people are streaming it on that platform. Apple’s three launch events last fall each garnered millions of people watching live on YouTube. It’s also available streaming directly on Apple’s website, which isn’t counted in the YouTube numbers.— Kif Leswing\nData point: iPads have been on a hot streak\nVarious models of the Apple Inc. iPad at the company’s Yeouido store during its opening in Seoul, South Korea, on Friday, Feb. 26, 2021.Jean Chung | Bloomberg | Getty Images\nAs Apple prepares to potentially release new iPads, remember that the product has had a great pandemic:In the fourth calendar quarter of 2020, Apple shipped $8.44 billion in iPads — which was up 41% year over year.— Kif Leswing\nApple’s spring events are typically more muted than its fall launch extravaganzas\nApple is best known for its fall launch events, where it reveals new iPhones, but it’s no stranger to hosting somewhat lower-profile events in the spring.\nApple didn’t hold a spring event in 2020 due to the onset of the coronavirus pandemic and instead launched new iPads and other gadgets on its website. In 2019, Apple’s spring announcement focused on services such asApple TV+and theApple Card. But it also announced new iPads in 2018 during an education-focused event at a school in Chicago.\nLast fall, Apple broadcast three prerecorded product launch events in three months, each of which garnered millions of live viewers on YouTube.— Kif Leswing\nYes, the Apple online store is down. No, it’s not a problem, it’s a tradition.\nScreenshot/Apple.com\nOne of Apple’s silliest traditions is that on the morning of an event it pulls its online Apple store down, giving up a few hours of online sales in exchange for building hype over its new products. Apple has done this for years, and technology has certainly gotten to the point where Apple could update its store without downtime — it does it all the time — but why mess with a tradition?— Kif Leswing\nWhat’s at stake for Apple?\nI wrote yesterday about some of thetensions bubbling under the surface at Apple. Yes, this is just another product event, but there are a lot of headaches on the horizon that could threaten its growth, especially in the App Store.\nThere’s the war of words withFacebookover theimpending iOS privacy feature. There’s the upcoming trial with Epic Games that centers on Apple’s control of the App Store. And then there’s Apple’s dependence on China, which is an obvious target for Apple critics. (Just ask Peter Thiel.)\nRead all about it right here.\n— Steve Kovach\nCook gets ready to kick off the event\nAppleCEO Tim Cook is gearing up for Tuesday’s “Spring Loaded” event, where the company is expected to announce new iPads and potentially a handful of other products. “It’s a beautiful spring morning for an #AppleEvent! See you soon,” Cook tweeted.\n— Jessica Bursztynsky","news_type":1},"isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572496817285200","authorId":"3572496817285200","name":"terry89","avatar":"https://static.tigerbbs.com/a8f3d3a49b2f88f3d66f162d57b571e1","crmLevel":2,"crmLevelSwitch":0,"idStr":"3572496817285200","authorIdStr":"3572496817285200"},"content":"pls comment on my response","text":"pls comment on my response","html":"pls comment on my response"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378104931,"gmtCreate":1619008013823,"gmtModify":1704718190314,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Bring me the moon!","listText":"Bring me the moon!","text":"Bring me the moon!","images":[{"img":"https://static.tigerbbs.com/619105afbeb5fde5015b6a6bda2b1180","width":"1600","height":"2481"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378104931","isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":378102246,"gmtCreate":1619007885385,"gmtModify":1704718187889,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASXC\">$Asensus Surgical, Inc.(ASXC)$</a>Down to earth..sad","listText":"<a href=\"https://laohu8.com/S/ASXC\">$Asensus Surgical, Inc.(ASXC)$</a>Down to earth..sad","text":"$Asensus Surgical, Inc.(ASXC)$Down to earth..sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378102246","isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":151618757,"gmtCreate":1625080937979,"gmtModify":1703735709577,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hi allgive opinion..i am new on this stock. Should i sell or hold?","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hi allgive opinion..i am new on this stock. Should i sell or hold?","text":"$CEL-SCI Corp(CVM)$Hi allgive opinion..i am new on this stock. Should i sell or hold?","images":[{"img":"https://static.tigerbbs.com/37e23442e9639e8f453bac2e6914f932","width":"1600","height":"2844"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":5,"repostSize":2,"link":"https://ttm.financial/post/151618757","isVote":1,"tweetType":1,"viewCount":1895,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":378107504,"gmtCreate":1619008153908,"gmtModify":1704718192748,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/378107504","repostId":"1193736432","repostType":4,"repost":{"id":"1193736432","kind":"news","pubTimestamp":1618966262,"share":"https://ttm.financial/m/news/1193736432?lang=&edition=fundamental","pubTime":"2021-04-21 08:51","market":"us","language":"en","title":"Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1193736432","media":"cnbc","summary":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.Apple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.Investors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.Here are some of the highlight announcements, but scroll down to see","content":"<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 08:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/20/apple-event-live-updates.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1193736432","content_text":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\nApple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.\nInvestors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.\nHere are some of the highlight announcements, but scroll down to see more.\n\nApple Card features for teens and families\nPodcast subscriptions\nAirTag lost item finder\nA purple iPhone 12\nA new Apple TV boxandremote\niMacs in seven colors with Apple’s M1 chip\nImproved iPad Pros with Apple’s M1 chip\n\nApple announces updated iPad Pros with chip from desktop computers\nApple said on Tuesday that it will release new high-end iPad Pros that use the company’s M1 chip, which is also used in its Mac computers. Previously, iPads used A-series chips, which are what powers the company’s iPhones. Apple says it is the most powerful tablet on the market.\nIt also includes an improved USB-C connector that will allow the iPad to connect to higher-resolution monitors and download images from a camera more quickly.\nThe 12.9-inch iPad Pro features an improved screen using an array of LEDs that is brighter and has better color resolution than previous displays using a technology called Mini-LED.\niPad ProSource: Apple Inc.\nThe iPad Pro will also have a 12-megapixel front-facing camera with an ultrawide lens that can automatically pan to keep human subjects in the shot.\nSome models will include 5G support, Apple said. The 11-inch model starts at $799, and the 12.9-inch model costs $1,099. They will be available for preorder on April 30 and will ship in late May.— Kif Leswing\niPad ProSource: Apple Inc.\nApple announces new iMac models that come in different colors\nApple launches new iMac.Source: Apple Inc.\nThese iMacs are powered by Apple's custom M1 silicon, not Intel processors. The computers have a new, thinner aluminum design, and they come in red, blue, purple, orange, yellow, silver, and green. The new thinner design looks a lot like a big iPad.\nApple launches new iMac with new colors.Source: Apple Inc.\nApple says the volume of the computer has been reduced by 50%, resulting in a smaller computer that can fit on a desk more easily. It comes with a 24-inch built-in display and an improved camera that can record 1080p video in low light. Apple says the display runs at \"4.5K\" resolution.\nIt ships with a new magnetic power connector reminiscent of Apple's previous MagSafe laptop chargers and a slightly updated keyboard with an emoji key and a fingerprint sensor. Apple's mouses and keyboard come in the same colors as the new iMacs.\nThe entry-level model costs $1,299, and an upgraded version costs $1,499. The new iMacs will go up for preorder on April 30 and will ship in the second half of May, Apple said.\nApple's first iMacs, released 20 years ago, also came in different colors.\nSource: Apple Inc.\nThe Apple TV finally has a brand-new remoteApple Inc.\nApple is finally rolling out a new, redesigned remote for the Apple TV. It's made of aluminum and has dedicated buttons for navigating menus, which should solve some of the headaches caused by the earlier remote. It will ship in the second half of May with the new Apple TV 4K, which costs $179 or $199 depending on the model.\n— Jessica Bursztynsky\nApple updates Apple TV 4K box with new processor\nApple announced that its Apple TV 4K box has been updated with a new processor, and it will be able to handle high frame rate HDR video which will result in displaying smoother, more colorful sports events.\nIt will also include a new feature that will use the iPhone's camera to tune the TV's picture quality.\nIt also comes with a completely redesigned remote made of aluminum with physical buttons, instead of the old remote’s touchpad. It can also control your TV’s power. Instead of a touchpad, it has a wheel for controlling the display.\nIt starts at $179 for 32GB of storage. It goes up for preorder on April 30 and will start shipping in the second half of May, Apple said.— Kif Leswing\nApple announces long-expected lost-item tracker called AirTag\n\nApple announced AirTag, calling it an iPhone accessory, priced at $29 for one or $99 for four. It will be on store shelves on April 30.\nIt uses Apple technology called Find My, which uses a network of iPhones to find lost objects. It’s using a technique Apple calls “precision finding” that it says is privacy-sensitive.\nThis product has been the source of some scrutiny from lawmakers who have heard that Apple is privileging its own lost-item trackers over others’ using anticompetitive practices and access to the iPhone operating system. Find My opened to third-party accessory makers last month.— Kif Leswing\nApple introduces new iPhone 12 color: Purple\nApple launches a new purple color iPhone for Spring.Source: Apple\nIt goes up for preorder on Friday and will ship on April 30.— Kif Leswing\nApple launching podcast subscription service\nApple announced that it’s launching its podcast subscription service next month, putting itself up further against Spotify and other competitors in the audio streaming wars.\nThe company is also redesigning its Apple Podcast app.\n— Jessica Bursztynsky\nApple says that credit scores are unfair, expands Apple Card to kids over 13 years old\nCEO Tim Cook said Apple will allow partners and spouses to share a credit line on a credit card, allowing both people to build credit scores. It’s also introducing features for families and teenagers. Apple was notably under fire fromco-founder Steve Wozniakafter people discovered that sometimes spouses had different credit limits.— Kif Leswing\nApple CEO Tim Cook kicks off the event\nTim Cook, CEO of Apple, speaks during an Apple Event on April 20th, 2021.Source: Apple Inc.\nWalking around Apple Park, Apple’s campus in Cupertino, California, Apple CEO Tim Cook kicked off the event with factoids about Apple’s environmental efforts, saying that Apple is carbon-neutral and hopes to remove 1 million tons of carbon from the environment per year.— Kif Leswing\nOver 360,000 people livestreaming Apple launch on YouTube\nAs Apple’s event kicks off, YouTube shows more than 360,000 people are streaming it on that platform. Apple’s three launch events last fall each garnered millions of people watching live on YouTube. It’s also available streaming directly on Apple’s website, which isn’t counted in the YouTube numbers.— Kif Leswing\nData point: iPads have been on a hot streak\nVarious models of the Apple Inc. iPad at the company’s Yeouido store during its opening in Seoul, South Korea, on Friday, Feb. 26, 2021.Jean Chung | Bloomberg | Getty Images\nAs Apple prepares to potentially release new iPads, remember that the product has had a great pandemic:In the fourth calendar quarter of 2020, Apple shipped $8.44 billion in iPads — which was up 41% year over year.— Kif Leswing\nApple’s spring events are typically more muted than its fall launch extravaganzas\nApple is best known for its fall launch events, where it reveals new iPhones, but it’s no stranger to hosting somewhat lower-profile events in the spring.\nApple didn’t hold a spring event in 2020 due to the onset of the coronavirus pandemic and instead launched new iPads and other gadgets on its website. In 2019, Apple’s spring announcement focused on services such asApple TV+and theApple Card. But it also announced new iPads in 2018 during an education-focused event at a school in Chicago.\nLast fall, Apple broadcast three prerecorded product launch events in three months, each of which garnered millions of live viewers on YouTube.— Kif Leswing\nYes, the Apple online store is down. No, it’s not a problem, it’s a tradition.\nScreenshot/Apple.com\nOne of Apple’s silliest traditions is that on the morning of an event it pulls its online Apple store down, giving up a few hours of online sales in exchange for building hype over its new products. Apple has done this for years, and technology has certainly gotten to the point where Apple could update its store without downtime — it does it all the time — but why mess with a tradition?— Kif Leswing\nWhat’s at stake for Apple?\nI wrote yesterday about some of thetensions bubbling under the surface at Apple. Yes, this is just another product event, but there are a lot of headaches on the horizon that could threaten its growth, especially in the App Store.\nThere’s the war of words withFacebookover theimpending iOS privacy feature. There’s the upcoming trial with Epic Games that centers on Apple’s control of the App Store. And then there’s Apple’s dependence on China, which is an obvious target for Apple critics. (Just ask Peter Thiel.)\nRead all about it right here.\n— Steve Kovach\nCook gets ready to kick off the event\nAppleCEO Tim Cook is gearing up for Tuesday’s “Spring Loaded” event, where the company is expected to announce new iPads and potentially a handful of other products. “It’s a beautiful spring morning for an #AppleEvent! See you soon,” Cook tweeted.\n— Jessica Bursztynsky","news_type":1},"isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3572496817285200","authorId":"3572496817285200","name":"terry89","avatar":"https://static.tigerbbs.com/a8f3d3a49b2f88f3d66f162d57b571e1","crmLevel":2,"crmLevelSwitch":0,"idStr":"3572496817285200","authorIdStr":"3572496817285200"},"content":"pls comment on my response","text":"pls comment on my response","html":"pls comment on my response"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140473027,"gmtCreate":1625670618569,"gmtModify":1703746193035,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>letters for investor! Please read it.","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>letters for investor! Please read it.","text":"$CEL-SCI Corp(CVM)$letters for investor! Please read it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":1,"link":"https://ttm.financial/post/140473027","isVote":1,"tweetType":1,"viewCount":1456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378139372,"gmtCreate":1619008971696,"gmtModify":1704718208361,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Pls response to my comment","listText":"Pls response to my comment","text":"Pls response to my comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/378139372","repostId":"1193736432","repostType":4,"repost":{"id":"1193736432","kind":"news","pubTimestamp":1618966262,"share":"https://ttm.financial/m/news/1193736432?lang=&edition=fundamental","pubTime":"2021-04-21 08:51","market":"us","language":"en","title":"Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1193736432","media":"cnbc","summary":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.Apple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.Investors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.Here are some of the highlight announcements, but scroll down to see","content":"<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere’s everything Apple just announced: New iPad Pros, colorful iMacs, AirTags and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 08:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/20/apple-event-live-updates.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\n...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.cnbc.com/2021/04/20/apple-event-live-updates.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1193736432","content_text":"Applejust held its first product launch event of the year, where it announced a colorful new iMac and an updated iPad Pro with 5G and the M1 chip that’s also used in the company’s desktop computers.\nApple also announced an AirTag lost-device tracking gadget and a refreshed Apple TV 4K with a brand-new remote.\nInvestors didn’t appear to be impressed by the news. Shares of Apple were down about 2% after the product event wrapped up.\nHere are some of the highlight announcements, but scroll down to see more.\n\nApple Card features for teens and families\nPodcast subscriptions\nAirTag lost item finder\nA purple iPhone 12\nA new Apple TV boxandremote\niMacs in seven colors with Apple’s M1 chip\nImproved iPad Pros with Apple’s M1 chip\n\nApple announces updated iPad Pros with chip from desktop computers\nApple said on Tuesday that it will release new high-end iPad Pros that use the company’s M1 chip, which is also used in its Mac computers. Previously, iPads used A-series chips, which are what powers the company’s iPhones. Apple says it is the most powerful tablet on the market.\nIt also includes an improved USB-C connector that will allow the iPad to connect to higher-resolution monitors and download images from a camera more quickly.\nThe 12.9-inch iPad Pro features an improved screen using an array of LEDs that is brighter and has better color resolution than previous displays using a technology called Mini-LED.\niPad ProSource: Apple Inc.\nThe iPad Pro will also have a 12-megapixel front-facing camera with an ultrawide lens that can automatically pan to keep human subjects in the shot.\nSome models will include 5G support, Apple said. The 11-inch model starts at $799, and the 12.9-inch model costs $1,099. They will be available for preorder on April 30 and will ship in late May.— Kif Leswing\niPad ProSource: Apple Inc.\nApple announces new iMac models that come in different colors\nApple launches new iMac.Source: Apple Inc.\nThese iMacs are powered by Apple's custom M1 silicon, not Intel processors. The computers have a new, thinner aluminum design, and they come in red, blue, purple, orange, yellow, silver, and green. The new thinner design looks a lot like a big iPad.\nApple launches new iMac with new colors.Source: Apple Inc.\nApple says the volume of the computer has been reduced by 50%, resulting in a smaller computer that can fit on a desk more easily. It comes with a 24-inch built-in display and an improved camera that can record 1080p video in low light. Apple says the display runs at \"4.5K\" resolution.\nIt ships with a new magnetic power connector reminiscent of Apple's previous MagSafe laptop chargers and a slightly updated keyboard with an emoji key and a fingerprint sensor. Apple's mouses and keyboard come in the same colors as the new iMacs.\nThe entry-level model costs $1,299, and an upgraded version costs $1,499. The new iMacs will go up for preorder on April 30 and will ship in the second half of May, Apple said.\nApple's first iMacs, released 20 years ago, also came in different colors.\nSource: Apple Inc.\nThe Apple TV finally has a brand-new remoteApple Inc.\nApple is finally rolling out a new, redesigned remote for the Apple TV. It's made of aluminum and has dedicated buttons for navigating menus, which should solve some of the headaches caused by the earlier remote. It will ship in the second half of May with the new Apple TV 4K, which costs $179 or $199 depending on the model.\n— Jessica Bursztynsky\nApple updates Apple TV 4K box with new processor\nApple announced that its Apple TV 4K box has been updated with a new processor, and it will be able to handle high frame rate HDR video which will result in displaying smoother, more colorful sports events.\nIt will also include a new feature that will use the iPhone's camera to tune the TV's picture quality.\nIt also comes with a completely redesigned remote made of aluminum with physical buttons, instead of the old remote’s touchpad. It can also control your TV’s power. Instead of a touchpad, it has a wheel for controlling the display.\nIt starts at $179 for 32GB of storage. It goes up for preorder on April 30 and will start shipping in the second half of May, Apple said.— Kif Leswing\nApple announces long-expected lost-item tracker called AirTag\n\nApple announced AirTag, calling it an iPhone accessory, priced at $29 for one or $99 for four. It will be on store shelves on April 30.\nIt uses Apple technology called Find My, which uses a network of iPhones to find lost objects. It’s using a technique Apple calls “precision finding” that it says is privacy-sensitive.\nThis product has been the source of some scrutiny from lawmakers who have heard that Apple is privileging its own lost-item trackers over others’ using anticompetitive practices and access to the iPhone operating system. Find My opened to third-party accessory makers last month.— Kif Leswing\nApple introduces new iPhone 12 color: Purple\nApple launches a new purple color iPhone for Spring.Source: Apple\nIt goes up for preorder on Friday and will ship on April 30.— Kif Leswing\nApple launching podcast subscription service\nApple announced that it’s launching its podcast subscription service next month, putting itself up further against Spotify and other competitors in the audio streaming wars.\nThe company is also redesigning its Apple Podcast app.\n— Jessica Bursztynsky\nApple says that credit scores are unfair, expands Apple Card to kids over 13 years old\nCEO Tim Cook said Apple will allow partners and spouses to share a credit line on a credit card, allowing both people to build credit scores. It’s also introducing features for families and teenagers. Apple was notably under fire fromco-founder Steve Wozniakafter people discovered that sometimes spouses had different credit limits.— Kif Leswing\nApple CEO Tim Cook kicks off the event\nTim Cook, CEO of Apple, speaks during an Apple Event on April 20th, 2021.Source: Apple Inc.\nWalking around Apple Park, Apple’s campus in Cupertino, California, Apple CEO Tim Cook kicked off the event with factoids about Apple’s environmental efforts, saying that Apple is carbon-neutral and hopes to remove 1 million tons of carbon from the environment per year.— Kif Leswing\nOver 360,000 people livestreaming Apple launch on YouTube\nAs Apple’s event kicks off, YouTube shows more than 360,000 people are streaming it on that platform. Apple’s three launch events last fall each garnered millions of people watching live on YouTube. It’s also available streaming directly on Apple’s website, which isn’t counted in the YouTube numbers.— Kif Leswing\nData point: iPads have been on a hot streak\nVarious models of the Apple Inc. iPad at the company’s Yeouido store during its opening in Seoul, South Korea, on Friday, Feb. 26, 2021.Jean Chung | Bloomberg | Getty Images\nAs Apple prepares to potentially release new iPads, remember that the product has had a great pandemic:In the fourth calendar quarter of 2020, Apple shipped $8.44 billion in iPads — which was up 41% year over year.— Kif Leswing\nApple’s spring events are typically more muted than its fall launch extravaganzas\nApple is best known for its fall launch events, where it reveals new iPhones, but it’s no stranger to hosting somewhat lower-profile events in the spring.\nApple didn’t hold a spring event in 2020 due to the onset of the coronavirus pandemic and instead launched new iPads and other gadgets on its website. In 2019, Apple’s spring announcement focused on services such asApple TV+and theApple Card. But it also announced new iPads in 2018 during an education-focused event at a school in Chicago.\nLast fall, Apple broadcast three prerecorded product launch events in three months, each of which garnered millions of live viewers on YouTube.— Kif Leswing\nYes, the Apple online store is down. No, it’s not a problem, it’s a tradition.\nScreenshot/Apple.com\nOne of Apple’s silliest traditions is that on the morning of an event it pulls its online Apple store down, giving up a few hours of online sales in exchange for building hype over its new products. Apple has done this for years, and technology has certainly gotten to the point where Apple could update its store without downtime — it does it all the time — but why mess with a tradition?— Kif Leswing\nWhat’s at stake for Apple?\nI wrote yesterday about some of thetensions bubbling under the surface at Apple. Yes, this is just another product event, but there are a lot of headaches on the horizon that could threaten its growth, especially in the App Store.\nThere’s the war of words withFacebookover theimpending iOS privacy feature. There’s the upcoming trial with Epic Games that centers on Apple’s control of the App Store. And then there’s Apple’s dependence on China, which is an obvious target for Apple critics. (Just ask Peter Thiel.)\nRead all about it right here.\n— Steve Kovach\nCook gets ready to kick off the event\nAppleCEO Tim Cook is gearing up for Tuesday’s “Spring Loaded” event, where the company is expected to announce new iPads and potentially a handful of other products. “It’s a beautiful spring morning for an #AppleEvent! See you soon,” Cook tweeted.\n— Jessica Bursztynsky","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":351941594,"gmtCreate":1616557269918,"gmtModify":1704795624236,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>hmmm,where gone the green days!","listText":"<a href=\"https://laohu8.com/S/EXPR\">$Express,(EXPR)$</a>hmmm,where gone the green days!","text":"$Express,(EXPR)$hmmm,where gone the green days!","images":[{"img":"https://static.tigerbbs.com/fc93333f1de6a97fdc794a62c933030a","width":"1600","height":"2844"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/351941594","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":898034101,"gmtCreate":1628449035103,"gmtModify":1703506275696,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GSAT\">$Globalstar(GSAT)$</a>Hoping after Q2 Aug 2021 Earning reports is out,price will change as forecasted. Good luck!","listText":"<a href=\"https://laohu8.com/S/GSAT\">$Globalstar(GSAT)$</a>Hoping after Q2 Aug 2021 Earning reports is out,price will change as forecasted. Good luck!","text":"$Globalstar(GSAT)$Hoping after Q2 Aug 2021 Earning reports is out,price will change as forecasted. Good luck!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/898034101","isVote":1,"tweetType":1,"viewCount":387,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378198954,"gmtCreate":1619008500378,"gmtModify":1704718198297,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Tell me more","listText":"Tell me more","text":"Tell me more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378198954","repostId":"2129871399","repostType":2,"repost":{"id":"2129871399","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1619007453,"share":"https://ttm.financial/m/news/2129871399?lang=&edition=fundamental","pubTime":"2021-04-21 20:17","market":"us","language":"en","title":"BRIEF-Bit Digital Reports New 40MW Agreement With Compute North","url":"https://stock-news.laohu8.com/highlight/detail?id=2129871399","media":"Reuters","summary":"April 21 (Reuters) - Bit Digital Inc   :   * BIT DIGITAL EXPANDS NORTH AMERICAN FOOTPRINT WITH NEW 4","content":"<html><body><p>April 21 (Reuters) - Bit Digital Inc   :</p><p>   * BIT DIGITAL EXPANDS <a href=\"https://laohu8.com/S/NAIT.UK\">NORTH AMERICAN</a> FOOTPRINT WITH NEW 40MW AGREEMENT WITH COMPUTE NORTH</p><p>   * BIT DIGITAL INC - AS PART OF AGREEMENT, CO WILL DEPLOY AN ADDITIONAL 13,000 ASIC MINERS AT COMPUTE NORTH FACILITIES IN UNITED STATES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bit Digital Reports New 40MW Agreement With Compute North</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bit Digital Reports New 40MW Agreement With Compute North\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-21 20:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>April 21 (Reuters) - Bit Digital Inc   :</p><p>   * BIT DIGITAL EXPANDS <a href=\"https://laohu8.com/S/NAIT.UK\">NORTH AMERICAN</a> FOOTPRINT WITH NEW 40MW AGREEMENT WITH COMPUTE NORTH</p><p>   * BIT DIGITAL INC - AS PART OF AGREEMENT, CO WILL DEPLOY AN ADDITIONAL 13,000 ASIC MINERS AT COMPUTE NORTH FACILITIES IN UNITED STATES</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DLR":"数字房地产信托公司","BTBT":"Bit Digital, Inc.","NGD":"New Gold"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129871399","content_text":"April 21 (Reuters) - Bit Digital Inc   :   * BIT DIGITAL EXPANDS NORTH AMERICAN FOOTPRINT WITH NEW 40MW AGREEMENT WITH COMPUTE NORTH   * BIT DIGITAL INC - AS PART OF AGREEMENT, CO WILL DEPLOY AN ADDITIONAL 13,000 ASIC MINERS AT COMPUTE NORTH FACILITIES IN UNITED STATESSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178844705,"gmtCreate":1626802004807,"gmtModify":1703765532381,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Up..up..up on the way...????","listText":"Up..up..up on the way...????","text":"Up..up..up on the way...????","images":[{"img":"https://static.tigerbbs.com/d7c09624f7153c0394e2cdc30065185e","width":"1600","height":"1911"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/178844705","isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":146836492,"gmtCreate":1626064895516,"gmtModify":1703752659982,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Is this dip just a momentum, after recent orders delivered?","listText":"Is this dip just a momentum, after recent orders delivered?","text":"Is this dip just a momentum, after recent orders delivered?","images":[{"img":"https://static.tigerbbs.com/1f5e7d1e70be72971e28865eb179bb03","width":"1600","height":"2895"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/146836492","isVote":1,"tweetType":1,"viewCount":337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":140472037,"gmtCreate":1625670771129,"gmtModify":1703746199206,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Latest news updated.","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Latest news updated.","text":"$CEL-SCI Corp(CVM)$Latest news updated.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140472037","isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140447431,"gmtCreate":1625670536723,"gmtModify":1703746189889,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Great articles&nbsp; to shares","listText":"Great articles&nbsp; to shares","text":"Great articles to shares","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140447431","repostId":"2149397016","repostType":2,"repost":{"id":"2149397016","kind":"news","pubTimestamp":1625659200,"share":"https://ttm.financial/m/news/2149397016?lang=&edition=fundamental","pubTime":"2021-07-07 20:00","market":"us","language":"en","title":"CEL-SCI Corporation Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2149397016","media":"Business Wire","summary":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a","content":"<html><body><p><b>VIENNA, Va., July 07, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/CVM\">CEL-SCI Corp</a>oration<b> (NYSE American: CVM)</b> today issued a letter to its shareholders.</p>\n<p>Dear CEL-SCI shareholders:</p>\n<p>The purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.</p>\n<p><b><i>Very Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients</i></b></p>\n<p>On June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.</p>\n<p>Our Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus<b> </b>radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.</p>\n<p>That means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.</p>\n<p><b><i>The Study Design is Based on National Comprehensive Cancer Network</i> <i>(NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful</i></b></p>\n<p>Let me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.</p>\n<p>Patients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of &lt;0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.</p>\n<p><b><i>The Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding</i></b></p>\n<p>The analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.</p>\n<p>We have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.</p>\n<p><b><i>False Assertions Addressed </i></b></p>\n<p>Some false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact <a href=\"https://laohu8.com/S/AONE\">one</a> of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.</p>\n<p>We intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?</p>\n<p>We are talking about a clear long term statistically significant survival benefit in <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.</p>\n<p>Other false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.</p>\n<p><b><i>Support From the Independent Statistician</i></b></p>\n<p>We are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:</p>\n<p>(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)</p>\n<p><b><i>CEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been &gt;30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. </i></b></p>\n<p><b><i>The decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:</i></b></p>\n<ul>\n<li><b><i>The primary efficacy endpoint remains overall survival</i></b>\n<ul>\n<li><b><i>Efficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.</i></b></li>\n<li><b><i>Analysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study </i></b></li>\n<li><b><i>Survival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery</i></b></li>\n<li><b><i>Model results are robust: </i></b>\n<ul>\n<li><b><i>Statistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n<li><b><i>Statistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n</ul></li>\n</ul></li>\n<li><b><i>The study did not encounter any overall safety issues.</i></b>\n<ul>\n<li><b><i>Every one of the above analyses were prospectively defined in the SAP. </i></b></li>\n</ul></li>\n</ul>\n<p><b><i>P-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:</i></b></p>\n<ul>\n<li><b><i>Collecting additional data.</i></b></li>\n<li><b><i>Dropping aberrant data.</i></b></li>\n<li><b><i>Focusing on alternative measures.</i></b></li>\n<li><b><i>Changing the analyses method.</i></b></li>\n</ul>\n<p><b><i>Specifically: </i></b></p>\n<ul>\n<li><b><i>We collected the data pre-specified in the protocol and eCRF.</i></b></li>\n<li><b><i>We did not drop any data; we used the NCCN low risk definition and we used the ITT population.</i></b></li>\n<li><b><i>We focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).</i></b></li>\n</ul>\n<p><b><i>We followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.</i></b></p>\n<p><b><i>Based on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" </i></b></p>\n<p>We believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.</p>\n<p><b><i>Do Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?</i></b></p>\n<p>I believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?</p>\n<p>Uncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.</p>\n<p>We have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"<i>neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\"</i>.</p>\n<p><b><i>Closing</i></b></p>\n<p>In closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.</p>\n<p>In talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"</p>\n<p>Thank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.</p>\n<p>Sincerely,</p>\n<p>Geert Kersten<br/>Chief Executive Officer</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</p>\n<p><i>* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.</i></p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210707005476/en/</span></p>\n<p><b>Contacts</b></p>\n<p>COMPANY CONTACT:<br/>Gavin de Windt<br/>CEL-SCI Corporation<b> </b><br/>(703) 506-9460</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CEL-SCI Corporation Issues Letter to Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCEL-SCI Corporation Issues Letter to Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/nbtUTYW1SOiQDcaq8dPzOg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Lxq8Bg4KkcfIXxn6.npJFg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7486af1e6a88511bdd61fb03476b6e56","relate_stocks":{"CVM":"CEL-SCI Corp"},"source_url":"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149397016","content_text":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.\nVery Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients\nOn June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.\nOur Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.\nThat means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.\nThe Study Design is Based on National Comprehensive Cancer Network (NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful\nLet me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.\nPatients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of <0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.\nThe Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding\nThe analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.\nWe have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.\nFalse Assertions Addressed \nSome false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact one of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.\nWe intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?\nWe are talking about a clear long term statistically significant survival benefit in one of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. Two different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.\nOther false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.\nSupport From the Independent Statistician\nWe are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:\n(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)\nCEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been >30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. \nThe decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:\n\nThe primary efficacy endpoint remains overall survival\n\nEfficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.\nAnalysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study \nSurvival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery\nModel results are robust: \n\nStatistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates\nStatistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates\n\n\nThe study did not encounter any overall safety issues.\n\nEvery one of the above analyses were prospectively defined in the SAP. \n\n\nP-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:\n\nCollecting additional data.\nDropping aberrant data.\nFocusing on alternative measures.\nChanging the analyses method.\n\nSpecifically: \n\nWe collected the data pre-specified in the protocol and eCRF.\nWe did not drop any data; we used the NCCN low risk definition and we used the ITT population.\nWe focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).\n\nWe followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.\nBased on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" \nWe believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.\nDo Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?\nI believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?\nUncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.\nWe have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\".\nClosing\nIn closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.\nIn talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"\nThank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.\nSincerely,\nGeert KerstenChief Executive Officer\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.\n* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210707005476/en/\nContacts\nCOMPANY CONTACT:Gavin de WindtCEL-SCI Corporation (703) 506-9460","news_type":1},"isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140446720,"gmtCreate":1625670384060,"gmtModify":1703746183945,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Some updates here,hope its beneficial&nbsp; for holders and shareholders.","listText":"Some updates here,hope its beneficial&nbsp; for holders and shareholders.","text":"Some updates here,hope its beneficial for holders and shareholders.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/140446720","repostId":"2149397016","repostType":2,"repost":{"id":"2149397016","kind":"news","pubTimestamp":1625659200,"share":"https://ttm.financial/m/news/2149397016?lang=&edition=fundamental","pubTime":"2021-07-07 20:00","market":"us","language":"en","title":"CEL-SCI Corporation Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2149397016","media":"Business Wire","summary":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a","content":"<html><body><p><b>VIENNA, Va., July 07, 2021</b>--(BUSINESS WIRE)--<a href=\"https://laohu8.com/S/CVM\">CEL-SCI Corp</a>oration<b> (NYSE American: CVM)</b> today issued a letter to its shareholders.</p>\n<p>Dear CEL-SCI shareholders:</p>\n<p>The purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.</p>\n<p><b><i>Very Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients</i></b></p>\n<p>On June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.</p>\n<p>Our Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus<b> </b>radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.</p>\n<p>That means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.</p>\n<p><b><i>The Study Design is Based on National Comprehensive Cancer Network</i> <i>(NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful</i></b></p>\n<p>Let me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.</p>\n<p>Patients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of &lt;0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.</p>\n<p><b><i>The Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding</i></b></p>\n<p>The analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.</p>\n<p>We have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.</p>\n<p><b><i>False Assertions Addressed </i></b></p>\n<p>Some false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact <a href=\"https://laohu8.com/S/AONE\">one</a> of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.</p>\n<p>We intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?</p>\n<p>We are talking about a clear long term statistically significant survival benefit in <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.</p>\n<p>Other false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.</p>\n<p><b><i>Support From the Independent Statistician</i></b></p>\n<p>We are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:</p>\n<p>(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)</p>\n<p><b><i>CEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been &gt;30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. </i></b></p>\n<p><b><i>The decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:</i></b></p>\n<ul>\n<li><b><i>The primary efficacy endpoint remains overall survival</i></b>\n<ul>\n<li><b><i>Efficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.</i></b></li>\n<li><b><i>Analysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study </i></b></li>\n<li><b><i>Survival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery</i></b></li>\n<li><b><i>Model results are robust: </i></b>\n<ul>\n<li><b><i>Statistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n<li><b><i>Statistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates</i></b></li>\n</ul></li>\n</ul></li>\n<li><b><i>The study did not encounter any overall safety issues.</i></b>\n<ul>\n<li><b><i>Every one of the above analyses were prospectively defined in the SAP. </i></b></li>\n</ul></li>\n</ul>\n<p><b><i>P-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:</i></b></p>\n<ul>\n<li><b><i>Collecting additional data.</i></b></li>\n<li><b><i>Dropping aberrant data.</i></b></li>\n<li><b><i>Focusing on alternative measures.</i></b></li>\n<li><b><i>Changing the analyses method.</i></b></li>\n</ul>\n<p><b><i>Specifically: </i></b></p>\n<ul>\n<li><b><i>We collected the data pre-specified in the protocol and eCRF.</i></b></li>\n<li><b><i>We did not drop any data; we used the NCCN low risk definition and we used the ITT population.</i></b></li>\n<li><b><i>We focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).</i></b></li>\n</ul>\n<p><b><i>We followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.</i></b></p>\n<p><b><i>Based on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" </i></b></p>\n<p>We believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.</p>\n<p><b><i>Do Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?</i></b></p>\n<p>I believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?</p>\n<p>Uncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.</p>\n<p>We have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"<i>neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\"</i>.</p>\n<p><b><i>Closing</i></b></p>\n<p>In closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.</p>\n<p>In talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"</p>\n<p>Thank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.</p>\n<p>Sincerely,</p>\n<p>Geert Kersten<br/>Chief Executive Officer</p>\n<p><b>Forward-Looking Statements</b></p>\n<p>This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</p>\n<p><i>* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.</i></p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210707005476/en/</span></p>\n<p><b>Contacts</b></p>\n<p>COMPANY CONTACT:<br/>Gavin de Windt<br/>CEL-SCI Corporation<b> </b><br/>(703) 506-9460</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CEL-SCI Corporation Issues Letter to Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCEL-SCI Corporation Issues Letter to Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 20:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/nbtUTYW1SOiQDcaq8dPzOg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/Lxq8Bg4KkcfIXxn6.npJFg--~B/aD0xNTA7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7486af1e6a88511bdd61fb03476b6e56","relate_stocks":{"CVM":"CEL-SCI Corp"},"source_url":"https://finance.yahoo.com/news/cel-sci-corporation-issues-letter-120000112.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2149397016","content_text":"VIENNA, Va., July 07, 2021--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.\nDear CEL-SCI shareholders:\nThe purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world’s largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine® (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval.\nVery Successful Pivotal Clinical Trial Results in Newly Diagnosed Advanced Primary Head and Neck Cancer Patients\nOn June 28, 2021 we announced results from our Phase 3 cancer study that proved that Multikine met all of the protocol required benefits stated in the study protocol in patients in the treatment arm receiving surgery and radiation as their standard therapies. Based on this we will be filing for and seeking FDA approval for the use of Multikine in the treatment of advanced primary head and neck cancer in this patient population.\nOur Phase 3 results showed a long-term 5-year overall survival (OS) benefit in this treatment arm that was robust and durable, with no safety issues, something not commonly seen with cancer drugs. In fact, the survival benefit increased over time and at 5-years the overall survival benefit reached an absolute 14.1% advantage for the Multikine treated arm over control (n=380, total study patients treated with surgery plus radiation), which is about a 29% improvement, control arm 48.6%, Multikine arm 62.7% survival.\nThat means an additional 21,000 patients would be alive at 5-years if all 155,000 eligible patients received Multikine plus surgery and radiation compared to the current standard of care (SOC). This is extremely significant because the survival benefit is large and the last approval for this indication was many decades ago. This is a serious disease with an unmet medical need, something very important when you apply for FDA approval.\nThe Study Design is Based on National Comprehensive Cancer Network (NCCN) Treatment Guidelines with 2 Different Treatment Arms, One of which was Very Successful\nLet me give you some details about the study design so that you can understand what happened. The NCCN Treatment Guidelines recommend to all physicians that the treatment for advanced primary head and neck cancer cases should be surgery first. Following the surgery there are two different treatment arms. The first treatment arm for the SOC is surgery plus radiation (about 40% of the patients) and the second treatment arm is surgery and concurrent radiochemotherapy (chemotherapy and radiation at the same time, about 60% of the patients). The toxicities in that radiochemotherapy arm can be very harsh, debilitating, and even fatal. In our protocol, the study endpoint was a 10% absolute improvement in OS when comparing the Multikine treatment regimen plus SOC vs SOC alone.\nPatients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result’s p-value was 0.0236 exceeding the protocol required p-value of <0.05. The study result’s Hazard Ratio was 0.68 exceeding the protocol required 0.721.\nThe Analysis of the 2 Different Treatments Arms is Permitted since it was Pre-Specified in the Protocol and Done Before Unblinding\nThe analysis for the successful treatment arm was pre-specified in the study protocol and also the study Statistical Analysis Plan (SAP). These documents specified that we would analyze and present to the FDA not only the combined results of the two treatment arms but also each individual treatment arm, such as Multikine followed by surgery and radiation (the successful group in the study) and also Multikine followed by surgery and radiochemotherapy. What we saw in the study is that patients who had been treated with Multikine followed by surgery and radiation had a robust and durable survival benefit that exceeded the parameters set for the study endpoints, but we also saw that when chemotherapy was added to radiation in the other treatment group, the survival benefit from Multikine was negated.\nWe have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology.\nFalse Assertions Addressed \nSome false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact one of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission.\nWe intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation?\nWe are talking about a clear long term statistically significant survival benefit in one of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. Two different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not.\nOther false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been \"data mining\" to find a benefit and \"p-value hacking\". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong.\nSupport From the Independent Statistician\nWe are confident that the decision to pursue a claim for a pre-defined treatment arm (Multikine followed by surgery and radiation) is sound and based on significant data and solid results. Here, we are being very transparent and sharing the following from our independent statistician:\n(Note: When the statistician says ‘low risk’ treatment group the statistician is referring to the surgery plus radiation treatment arm.)\nCEL-SCI developed Multikine to treat locally advanced SCCHN (Squamous cell carcinoma of the head and neck). It has been >30 years since any new therapy has been approved to treat the Stage 3-4 SCCHN. The CEL-SCI protocol and SAP were designed with a primary efficacy endpoint (overall survival) to be studied in three pre-defined populations with two clinically relevant starting points (randomization, surgery). The protocol pre-defined subgroup analyses are consistent with the literature and the SEER database; these include tumor stage, tumor location, surgical margin, risk group, and disease-directed therapy. This is the largest Phase 3 study ever conducted in locally advanced SCCHN. The study randomized patients at 78 sites on 3 continents. \nThe decision to pursue a claim for a pre-defined subgroup is supported by the following considerations:\n\nThe primary efficacy endpoint remains overall survival\n\nEfficacy target was met: The 0.68 hazard ratio for the low-risk subgroup was consistent with the previously targeted 0.721 hazard ratio to the entire population.\nAnalysis methods are robust: Statistical significance was reached for the pre-specified log rank test (primary analysis) in the key intent to treat (ITT) population and supported by other populations in the study \nSurvival outcomes are robust: Statistical significance was supported whether measuring from the time of randomization or surgery\nModel results are robust: \n\nStatistical significance was supported for the treatment low-risk interaction using the Cox proportional hazard model containing pre-specified covariates\nStatistical significance was supported for the low-risk subgroup using the Cox proportional hazard model containing pre-specified covariates\n\n\nThe study did not encounter any overall safety issues.\n\nEvery one of the above analyses were prospectively defined in the SAP. \n\n\nP-value hacking occurs when the original protocol and/or statistical analysis plan (SAP) are modified after the fact in the attempt to reach statistical significance:\n\nCollecting additional data.\nDropping aberrant data.\nFocusing on alternative measures.\nChanging the analyses method.\n\nSpecifically: \n\nWe collected the data pre-specified in the protocol and eCRF.\nWe did not drop any data; we used the NCCN low risk definition and we used the ITT population.\nWe focused on the protocol-specified primary efficacy endpoint (overall survival [OS]).\n\nWe followed the pre-planned analyses to compute [Overall Survival] OS hazard ratios and p-values.\nBased on all of the foregoing, NO \"data mining\" took place to support the (information in the CEL-SCI) press release.\" \nWe believe this very detailed statistical data will serve to inform those who are well versed in statistics as they apply to clinical trial data.\nDo Short Sellers Value Their Profits More Than the Tens of Thousands of Lives That Can Be Extended?\nI believe that there are people with a large incentive to drive the stock down since CEL-SCI had a 25% short position. Before we announced our Phase 3 data, it was understandable that some people would bet against our company and our drug since the outcome was uncertain. But now, the data clearly shows that Multikine extends life in 40% of newly diagnosed advanced primary head and neck cancer patients. In fact, after we file for FDA approval, should Multikine receive marketing clearance, tens of thousands of people may live longer five years after treatment. What kind of person continues to sell short and attack a company that can make this kind of difference in the lives of cancer patients?\nUncertainty from the fact that the chemotherapy treatment arm did not work allowed attacks on the stock. It looks as if the shorting volume on our stock on the day of the announcement was 56% of the daily volume and around 40% for the next few days (www.shortstockvolume.com/Chart/CVM/). That should not be possible since there are not enough shares to borrow and brokerage firms are supposed to check if stock is available to borrow before selling short. You draw your own conclusions.\nWe have followed all of the rules to achieve a very significant never before seen long term survival benefit in advanced primary head and neck cancer, for which no new therapy has come to market in decades. In addition, no safety issues were identified, something not seen in other cancer drugs. The disease indication represents an unmet medical need and in fact, Multikine has received an Orphan Drug designation from the FDA for the \"neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck (SCCHN)\".\nClosing\nIn closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval.\nIn talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades. As one physician wrote: \"Head and neck cancer is possibly the most horrific of all cancers. Not only does it take your life, but it takes your beauty, your voice and your dignity.\"\nThank you for your support and interest as we seek to help these patients. More data will be presented in peer reviewed publications.\nSincerely,\nGeert KerstenChief Executive Officer\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words \"intends,\" \"believes,\" \"anticipated,\" \"plans\" and \"expects,\" and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2020. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.\n* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210707005476/en/\nContacts\nCOMPANY CONTACT:Gavin de WindtCEL-SCI Corporation (703) 506-9460","news_type":1},"isVote":1,"tweetType":1,"viewCount":534,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":158685664,"gmtCreate":1625147852158,"gmtModify":1703737157271,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"?Great,really appreciate&nbsp; for such respond n comments..good wishes for all.","listText":"?Great,really appreciate&nbsp; for such respond n comments..good wishes for all.","text":"?Great,really appreciate for such respond n comments..good wishes for all.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158685664","repostId":"158398356","repostType":1,"repost":{"id":158398356,"gmtCreate":1625127750775,"gmtModify":1703736679400,"author":{"id":"3585222150655793","authorId":"3585222150655793","name":"Skyciti","avatar":"https://static.tigerbbs.com/f12b30dddbedf14f6cef0d78f22860c9","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3585222150655793","authorIdStr":"3585222150655793"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hold…..it will rocket soon.","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>Hold…..it will rocket soon.","text":"$CEL-SCI Corp(CVM)$Hold…..it will rocket soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/158398356","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151613571,"gmtCreate":1625080326793,"gmtModify":1703735706954,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>what happened? Should i hold or sell?&nbsp;","listText":"<a href=\"https://laohu8.com/S/CVM\">$CEL-SCI Corp(CVM)$</a>what happened? Should i hold or sell?&nbsp;","text":"$CEL-SCI Corp(CVM)$what happened? Should i hold or sell?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/151613571","isVote":1,"tweetType":1,"viewCount":245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102533358,"gmtCreate":1620223055174,"gmtModify":1704340414548,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CAN\">$Canaan Inc.(CAN)$</a>Not sure what canni do,hold or blood weeping!&nbsp;","listText":"<a href=\"https://laohu8.com/S/CAN\">$Canaan Inc.(CAN)$</a>Not sure what canni do,hold or blood weeping!&nbsp;","text":"$Canaan Inc.(CAN)$Not sure what canni do,hold or blood weeping!","images":[{"img":"https://static.tigerbbs.com/f07653b53b4ed4c23f4fb9fe97e9ce2f","width":"1600","height":"2844"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/102533358","isVote":1,"tweetType":1,"viewCount":166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":378193164,"gmtCreate":1619008382358,"gmtModify":1704718196358,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Tell me more","listText":"Tell me more","text":"Tell me more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378193164","repostId":"2129087941","repostType":4,"repost":{"id":"2129087941","kind":"highlight","pubTimestamp":1619006100,"share":"https://ttm.financial/m/news/2129087941?lang=&edition=fundamental","pubTime":"2021-04-21 19:55","market":"us","language":"en","title":"3 Stocks That Offer Explosive Potential Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2129087941","media":"Motley Fool","summary":"All of these companies have major catalysts ahead of them.","content":"<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.</p><p>These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.</p><p>Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker <b>NIO</b> (NYSE:NIO), EV charging network leader <b>ChargePoint Holdings</b> (NYSE:CHPT), and North American steelmaker <b>Nucor</b> (NYSE:NUE) could produce significant gains for shareholders in the years ahead.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fnioet7-hero-design.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"435\" referrerpolicy=\"no-referrer\"></p><p>The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.</p><h2>NIO: A massive and growing market</h2><p>As recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.</p><p>EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.</p><p>The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.</p><p>The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with<b> Ford</b> (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fchargepoint-ev-charging-for-multi-family1-copy.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: ChargePoint.</p><h2>ChargePoint: A network of vital infrastructure</h2><p>With more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.</p><p>It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.</p><p>President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.</p><p>Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. <b>General Motors</b> (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.</p><h2>Nucor: New records on the horizon</h2><p>Leading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"</p><p>There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be <a href=\"https://laohu8.com/S/AONE\">one</a> of the biggest beneficiaries of this as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top two low-cost steel producers in the U.S.</p><p>Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.</p><p>But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Offer Explosive Potential Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Offer Explosive Potential Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NUE":"纽柯钢铁"},"source_url":"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129087941","content_text":"Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker NIO (NYSE:NIO), EV charging network leader ChargePoint Holdings (NYSE:CHPT), and North American steelmaker Nucor (NYSE:NUE) could produce significant gains for shareholders in the years ahead.The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.NIO: A massive and growing marketAs recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with Ford (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.Image source: ChargePoint.ChargePoint: A network of vital infrastructureWith more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. General Motors (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.Nucor: New records on the horizonLeading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be one of the biggest beneficiaries of this as one of the top two low-cost steel producers in the U.S.Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378199690,"gmtCreate":1619008312910,"gmtModify":1704718195342,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"How?","listText":"How?","text":"How?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378199690","repostId":"1105485810","repostType":4,"repost":{"id":"1105485810","kind":"news","pubTimestamp":1619003862,"share":"https://ttm.financial/m/news/1105485810?lang=&edition=fundamental","pubTime":"2021-04-21 19:17","market":"fut","language":"en","title":"Three indirect ways investors can play the cryptocurrency craze","url":"https://stock-news.laohu8.com/highlight/detail?id=1105485810","media":"CNBC","summary":"The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo ha","content":"<div>\n<p>The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo has started letting users to buy, sell and hold bitcoin,ethereum,litecoin and bitcoin cash, the next ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Three indirect ways investors can play the cryptocurrency craze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThree indirect ways investors can play the cryptocurrency craze\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo has started letting users to buy, sell and hold bitcoin,ethereum,litecoin and bitcoin cash, the next ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.cnbc.com/2021/04/21/cryptocurrency-craze-three-indirect-ways-investors-can-play-it.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1105485810","content_text":"The cryptocurrency craze is quickly going mainstream.\nPayPal’s peer-to-peer payment service Venmo has started letting users to buy, sell and hold bitcoin,ethereum,litecoin and bitcoin cash, the next step in PayPal’s foray into digital assets.\nBut in some cases, investors might find more luck with indirect crypto plays than the currencies themselves, two traders told CNBC on Tuesday.\n“In this case — the rush to the mining — it’s better to sell the picks and shovels than necessarily go for the mined asset,” Chantico Global founder and CEO Gina Sanchez said on“Trading Nation.”\nPayPal, for one, will make “extraordinary fees” off Venmo’s move, said Sanchez, also chief market strategist at Lido Advisors.\n“We own PayPal in our portfolio [at Lido Advisors]. We also own other chip names like Nvidia and Intel,” she said. “You need two things to mine bitcoin: you need very powerful computers and you need electricity. Electricity’s harder to play, but the chip shortage is easier.”\nAs businesses embrace digital assets, companies that help facilitate crypto transactions could also win out, Strategic Wealth Partners president and CEO Mark Tepper said in the same interview.\n“Silvergate’sa bank ... that works with all the crypto companies out there. Venmo’s allowing its users to access crypto through Paxos, which happens to be a Silvergate customer. So Silvergate’s going to benefit from this whole Venmo deal,” Tepper said.\n“I really like them as a play and I think they’re actually going to benefit tremendously from what Venmo’s doing,” he said.\nAs for bitcoin itself, more hype will likely bring higher prices, Tepper said.\n“What’s really going to drive bitcoin higher is more and more adoption,” he said. “If Amazon ever were to all of a sudden accept payments in bitcoin, I think bitcoin would shoot to over 100,000 overnight. So, yes, the more you see companies adopt and embrace it, I think the higher bitcoin goes.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378190715,"gmtCreate":1619008261937,"gmtModify":1704718195019,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Say it again","listText":"Say it again","text":"Say it again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378190715","repostId":"1140867286","repostType":4,"repost":{"id":"1140867286","kind":"news","pubTimestamp":1619004558,"share":"https://ttm.financial/m/news/1140867286?lang=&edition=fundamental","pubTime":"2021-04-21 19:29","market":"us","language":"en","title":"Should You Buy Peloton Stock: What To Consider","url":"https://stock-news.laohu8.com/highlight/detail?id=1140867286","media":"seekingalpha","summary":"Summary\n\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of dema","content":"<p><b>Summary</b></p>\n<ul>\n <li>Peloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues.</li>\n <li>Peloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021, which beat market expectations, but its slowing revenue growth momentum led to its share price declining post-results.</li>\n <li>I like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors.</li>\n <li>But Peloton is not as attractive as an investment due to its rather rich valuations.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8b9a7cebe129367e4549d92aecef0d75\" tg-width=\"1536\" tg-height=\"1024\"><span>Photo by Maridav/iStock via Getty Images</span></p>\n<p><b>Elevator Pitch</b></p>\n<p>I assign a Neutral rating to Peloton Interactive, Inc.(NASDAQ:PTON).</p>\n<p>Peloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues. Peloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021 (YE June 30) which beat market expectations, but its slowing revenue growth momentum (versus +232% YoY revenue growth in 1Q FY 2021) led to its share price declining by -6% post-results.</p>\n<p>I like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors. Furthermore, Peloton is not as attractive as an investment due to its rather rich valuations. Peloton trades at consensus forward FY 2021 Enterprise Value-to-Revenue and EV/EBITDA multiples of 7.3 times and 91.8 times. These numbers will be more reasonable if PTON is a SaaS (Software-as-a-Service) company, but Peloton still derives over 80% of its revenue from product sales as opposed to digital subscriptions. As a result, I see Peloton Interactive, Inc's shares as a HOLD.</p>\n<p><b>Company Description</b></p>\n<p>Established in 2012 and listed on the NASDAQ in&nbsp;September 2020, Peloton Interactive, Inc.calls itself&nbsp;\"the largest interactive fitness platform in the world\" in the company's 2Q FY 2021 10-Q. Peloton has&nbsp;over 4.4 million members&nbsp;as of end-2020 (calendar year), and \"any individual who has a Peloton account through a paid Connected Fitness subscription, or a paid Peloton Digital subscription\" is&nbsp;counted as&nbsp;a member.</p>\n<p>PTON derived&nbsp;81% and 19%&nbsp;of its 1H FY 2021 revenue from Connected Fitness product sales (e.g. its Bike and Tread products) and subscription fees (for both Connected Fitness and Peloton Digital subscriptions), respectively. With regards to earnings contribution, the Connected Fitness products and the subscription business accounted for 72% and 18% of Peloton's top line in the first half of fiscal 2021. In terms of geographical sales mix, Peloton generated 95% of the company's 1H FY 2021 sales from North America, with other international markets contributing the remaining 5% of its revenue over the same period.</p>\n<p><b>Why Did Peloton Stock Drop?</b></p>\n<p>2020 was a great year for Peloton Interactive, Inc in terms of stock price performance, as the company's share price surged by +434% from $28.40 as of December 31, 2019 to $151.72 as of December 31, 2020. The same can't be said of 2021, as PTON's last traded price of $107.75 as of April 19, 2021 represents a year-to-date decline of -29%.</p>\n<p>Peloton's stock price has dropped significantly in 2021 year-to-date for a number of reasons.</p>\n<p>Firstly, investors are concerned that Work-From-Home or WFH tailwinds for Peloton will ease once the coronavirus pandemic wanes. Peloton has been a key beneficiary of an increasing number of people working and exercising at home due to COVID-19, but there is no certainty that such trends will persist post-pandemic. Based on&nbsp;data&nbsp;from&nbsp;<i>Bloomberg's COVID Vaccine Tracker</i>, 25.7% of the US population has already been fully vaccinated, while 39.9% of the people in the country have at least been administrated a single dose of the COVID-19 vaccine.</p>\n<p>In other words, the market is worried about more people returning to offices and exercising at gyms again and its impact on PTON's future performance. In response, Peloton&nbsp;stressed&nbsp;at the JMP Securities Technology Conference on March 1, 2021 that exercising at home \"is a trend that's here to stay\" and \"COVID just accelerated that trend.\" The company also added that \"people have found a way not only to replicate exercising outside of the home, but enjoy it more and perhaps are doing even more than they were even pre-pandemic\", based on its analysis of members' data.</p>\n<p>Nevertheless, it remains a significant unknown as to how consumers' behaviors will change and evolve post-pandemic.</p>\n<p>Secondly, Peloton has faced challenges in converting all of the consumer demand for its Connected Fitness products into actual sales.</p>\n<p>At the company's 2Q FY 2021 results briefing on February 4, 2021, Peloton&nbsp;acknowledged&nbsp;that \"our delivery wait times remain elevated.\" It also highlighted that \"West Coast port delays and COVID-related delivery challenges\" resulted in longer-than-expected \"order to delivery wait times\" and \"forced us to reschedule many deliveries.\"</p>\n<p>But Peloton is actively trying to address these issues. On April 1, 2021, Peloton disclosed that it had completed the acquisition of&nbsp;Precor, which it&nbsp;refers to&nbsp;as&nbsp;\"one of the largest global commercial fitness equipment providers with a significant U.S. manufacturing presence.\" This should help to ease Peloton's production capacity issues. Also, Peloton has also committed to an additional investment of&nbsp;$100 million&nbsp;with the aim of restoring delivery wait times to normalized levels by end of FY 2021 (June 30, 2022) at the latest.</p>\n<p>The key concerns here are that this could result in significant customer dissatisfaction and also lead investors to turn to other alternative options such as going back to the gyms (if possible) or buying other competing home fitness products.</p>\n<p>Thirdly, Peloton's stock price has been affected by product safety issues raised by the Consumer Product Safety Commission or CPSC.</p>\n<p>The CSPC published a&nbsp;press release&nbsp;on April 17, 2021 \"warning consumers about the danger of popular Peloton Tread+ exercise machine after multiple incidents of small children and a pet being injured beneath the machines.\" Peloton has responded with a&nbsp;media release&nbsp;of its own on the same day, stating that the CSPC press release is \"inaccurate and misleading\". The company also emphasized that \"there is no reason to stop using the Tread+, as long as all warnings and safety instructions are followed.\"</p>\n<p>Peloton's share price fell by -7% from $116.21 as of April 16, 2021 to $107.75 as of April 19, 2021 following CSPC's press release and Peloton's response. The company has an incredible brand and a strong following as evidenced by some of its fans having Peloton&nbsp;tattoos, so it might take more than a warning from the CSPC to hurt its future sales. However, it is worth following the developments relating to this matter on product safety issues to evaluate any potential damage to Peloton's brand.</p>\n<p>In a nutshell, the most important issue for long-term investors in Peloton is how consumers' attitudes towards home fitness &amp; exercise will change post-COVID, which will affect the company's future growth runway. On the other hand, product delivery bottlenecks should be resolved in time to come, while the product safety concerns could blow over soon as well.</p>\n<p><b>How Is Peloton Doing Financially?</b></p>\n<p>Peloton Interactive, Inc reported its most recent&nbsp;2Q FY 2021 financial results&nbsp;(October 1, 2020 to December 31, 2020 period) on February 4, 2021. The company's financial performance in the second quarter of the current fiscal year was above market expectations.</p>\n<p>PTON's revenue rose by +128% YoY from $466 million in 2Q FY 2020 to $1,065 million in 2Q FY 2021, which was approximately&nbsp;+3% better&nbsp;that what Wall Street had expected. This was driven by a +124% YoY increase in Connected Fitness product sales and a +153% YoY growth in subscription revenue. The company also reversed from a net loss per share of -$0.20 in 2Q FY 2020 to a positive earnings per share of $0.18 in 2Q FY 2021. This was more than double the sell-side analysts' quarterly consensus earnings estimate of&nbsp;$0.08 per share.</p>\n<p>However, Peloton's share price declined by -6% from $157.53 as of February 4, 2021 to $148.30 as of February 5, 2021 post-results. The company's stock price subsequently dropped to a year-to-date low of $101.35 on March 8, 2021. This suggests that Peloton's financial performance might not be as good as what it appears on paper, if one delves deeper.</p>\n<p>Notably, Peloton's YoY revenue growth narrowed significantly from +232% YoY in 1Q FY 2021 and +172% YoY in 4Q FY 2020 to +128% in 2Q FY 2021. PTON is guiding for&nbsp;$1.10 billion&nbsp;in revenue for 3Q FY 2021, which translates to a top line growth of +110% YoY in the next quarter. This could be attributable to both product delivery issues and demand normalization (highlighted earlier), but there is no escaping the fact that Peloton's revenue growth is slowing.</p>\n<p>In terms of operating metrics, it is noteworthy that the average workouts per month per subscribers for PTON has stabilized at&nbsp;20.7 and 21.1&nbsp;for 1Q FY 2021 and 2Q FY 2021 respectively. In comparison, Peloton's average workouts per month per subscribers jumped from 17.7 in 3Q FY 2020 to 24.7 in 4Q FY 2020. This could be another sign that home fitness demand is starting to normalize.</p>\n<p><b>PTON Stock Analysis</b></p>\n<p>There are a number of things that investors should like about Peloton Interactive, Inc as a business.</p>\n<p>One key characteristic of PTON's business is that the company has an amazing brand. As I indicated earlier, some of Peloton's followers even have the brand's logo tattooed on their bodies, which is the clearest indication of Peloton's brand equity. Also, consulting firm<i>Prophet</i>namedPeloton as the second most relevant brand in the US in 2021 based ona survey of approximately 13,000 consumers. Peloton only ranked behind Apple(NASDAQ:AAPL), and it beat other household brands like Lego, Costco(NASDAQ:COST)and Amazon(NASDAQ:AMZN). Prophet's studyhighlightsthat PTON \"earns the highest score for 'connects with me emotionally' via \"its online communities and its constantly expanding variety of workouts available live and prerecorded.\"</p>\n<p>Another key characteristic of Peloton's business is that it offers a compelling value proposition for consumers. A Connected Fitness subscription costs $39 per month, and the company's Connected Fitness products like bikes are priced at around a few thousand dollars ($1,895for flagship bike product) which can be paid in installments and used by all the people living together. In other words, the all-in cost of working out at home by using PTON's products and services are much cheaper than an annual individual gym membership subscription. In addition, an April 9, 2021<i>Wall Street Journal</i>articlecited Credit Suisse sell-side research which suggested that \"the monthly cost\" of \"a Peloton bike with a digital membership\" for a couple is \"87% below the cost\" of \"10 SoulCycle classes a month.\" Notably, Peloton's Average Net Monthly Connected Fitness Churncalculated as\"cancellations, net of reactivations\" divided by the number of Connected Fitness subscriptions was below 1% for both FY 2020 and FY 2019.</p>\n<p>Moving forward, Peloton has a long growth runway ahead, considering its multiple growth drivers.</p>\n<p>One growth driver is new products and cross-selling. It is telling that only3%of Peloton's Connected Fitness' subscribers have both Bike and Tread products from the company. PTONobservedat the recent earnings call that there has been a \"continued mix shift to (the new) Tread products\" andmentionedat the JMP Securities Technology Conference that \"two-product households\" are \"more engaged than people who had have 1 piece of equipment.\" Looking ahead, it is likely that Peloton can increase the proportion of its subscribers who have bought both the Bike and Tread products, and such \"two-product households\" could also be interested in more fitness courses and programs offered by the company leading to higher subscription revenue as well.</p>\n<p>Another key growth driver is potential synergies associated with the acquisition of Precor highlighted above. Although Peloton has a significant US consumer presence, it is not as strong in commercial and international markets, and Precor could help to fill in the gap. In the company's earlier press release announcing the Precor acquisition, Pelotonnotednew growth opportunities in channels like \"hotels, multifamily residences, and college and corporate campuses.\" Also, while Peloton generated 95% of its 1H FY 2021 revenue from North America as highlighted earlier, Precor hasa presencein \"90 countries around the world.\" PTON has already expanded into the UK and Canada, but there is a lot of room for further overseas expansion.</p>\n<p>On the flip side, the huge growth potential of the home fitness market inevitably attracts competition. One key competitor isMirrorreferred to as an \"interactive smart gym\" enabled by \"advanced camera technology and machine learning\", The Mirror is , which Lululemon(NASDAQ:LULU)acquired inmid-2020. Another one of Peloton's key competitors isTonal, which calls itself \"an all-in-one machine\" combining \"fitness and strength training with patented digital weight, machine learning, and expert coaching.\" Tonal has raised$450 millionin cumulative funding since its launch, and one of its notable investors include Amazon’s Alexa Fund.</p>\n<p>While I acknowledge that Peloton has a strong brand, the competitive landscape in the home fitness industry is still relatively unsettled. The market is growing, and one can't rule out more new entrants. More importantly, customer switching costs (i.e. a few thousand dollars for the Connected Fitness products) might not be sufficient to prevent consumers from switching to new products and other alternatives.</p>\n<p><b>Should You Buy Peloton Stock?</b></p>\n<p>I see Peloton stock as a HOLD, rather than a BUY. While Peloton is a good company, it is not a good investment as it stands now. PTON's valuations are rather rich, considering that the company still generates more than 80% of its sales from products, rather than digital subscriptions.</p>\n<p>The market values Peloton at 7.3 times consensus forward FY 2021 Enterprise Value-to-Revenue and 5.3 times consensus forward FY 2022 Enterprise Value-to-Revenue. The stock also trades at consensus forward FY 2021 and FY 2022 EV/EBITDA multiples of 91.8 times and 50.9 times, respectively.</p>\n<p>None of Peloton's direct peers are listed on a stand-alone basis, which makes peer valuation comparison challenging. PTON is much more expensive than its fitness peers based on forward EV/EBITDA multiples, although there is a significant divergence in Enterprise Value-to-Revenue ratios for the peer group.</p>\n<p><b>Peloton's Peer Valuation Comparison</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6f8be3d26f74a213f2aad2297c197307\" tg-width=\"904\" tg-height=\"605\"><span>Source: Author</span></p>\n<p>I have sourced the consensus numbers referenced in this article from S&amp;P Capital IQ.</p>\n<p>Peloton's key risk factors are a more significant normalization of home fitness demand post-COVID than earlier anticipated, further negative news flow relating to product safety issues, and stiffer-than-expected competition from rivals in the home fitness industry.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Peloton Stock: What To Consider</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Peloton Stock: What To Consider\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4420041-should-you-buy-peloton-stock-what-to-consider><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues.\nPeloton's revenue jumped by +...</p>\n\n<a href=\"https://seekingalpha.com/article/4420041-should-you-buy-peloton-stock-what-to-consider\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PTON":"Peloton Interactive, Inc."},"source_url":"https://seekingalpha.com/article/4420041-should-you-buy-peloton-stock-what-to-consider","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140867286","content_text":"Summary\n\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues.\nPeloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021, which beat market expectations, but its slowing revenue growth momentum led to its share price declining post-results.\nI like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors.\nBut Peloton is not as attractive as an investment due to its rather rich valuations.\n\nPhoto by Maridav/iStock via Getty Images\nElevator Pitch\nI assign a Neutral rating to Peloton Interactive, Inc.(NASDAQ:PTON).\nPeloton's share price is down -29% year-to-date, due to concerns over normalization of demand post-COVID, delays in product delivery, and product safety issues. Peloton's revenue jumped by +128% YoY to $1,065 million in 2Q FY 2021 (YE June 30) which beat market expectations, but its slowing revenue growth momentum (versus +232% YoY revenue growth in 1Q FY 2021) led to its share price declining by -6% post-results.\nI like Peloton as a business because it has a strong following and offers a compelling value proposition, but the company also has no lack of competitors. Furthermore, Peloton is not as attractive as an investment due to its rather rich valuations. Peloton trades at consensus forward FY 2021 Enterprise Value-to-Revenue and EV/EBITDA multiples of 7.3 times and 91.8 times. These numbers will be more reasonable if PTON is a SaaS (Software-as-a-Service) company, but Peloton still derives over 80% of its revenue from product sales as opposed to digital subscriptions. As a result, I see Peloton Interactive, Inc's shares as a HOLD.\nCompany Description\nEstablished in 2012 and listed on the NASDAQ in September 2020, Peloton Interactive, Inc.calls itself \"the largest interactive fitness platform in the world\" in the company's 2Q FY 2021 10-Q. Peloton has over 4.4 million members as of end-2020 (calendar year), and \"any individual who has a Peloton account through a paid Connected Fitness subscription, or a paid Peloton Digital subscription\" is counted as a member.\nPTON derived 81% and 19% of its 1H FY 2021 revenue from Connected Fitness product sales (e.g. its Bike and Tread products) and subscription fees (for both Connected Fitness and Peloton Digital subscriptions), respectively. With regards to earnings contribution, the Connected Fitness products and the subscription business accounted for 72% and 18% of Peloton's top line in the first half of fiscal 2021. In terms of geographical sales mix, Peloton generated 95% of the company's 1H FY 2021 sales from North America, with other international markets contributing the remaining 5% of its revenue over the same period.\nWhy Did Peloton Stock Drop?\n2020 was a great year for Peloton Interactive, Inc in terms of stock price performance, as the company's share price surged by +434% from $28.40 as of December 31, 2019 to $151.72 as of December 31, 2020. The same can't be said of 2021, as PTON's last traded price of $107.75 as of April 19, 2021 represents a year-to-date decline of -29%.\nPeloton's stock price has dropped significantly in 2021 year-to-date for a number of reasons.\nFirstly, investors are concerned that Work-From-Home or WFH tailwinds for Peloton will ease once the coronavirus pandemic wanes. Peloton has been a key beneficiary of an increasing number of people working and exercising at home due to COVID-19, but there is no certainty that such trends will persist post-pandemic. Based on data from Bloomberg's COVID Vaccine Tracker, 25.7% of the US population has already been fully vaccinated, while 39.9% of the people in the country have at least been administrated a single dose of the COVID-19 vaccine.\nIn other words, the market is worried about more people returning to offices and exercising at gyms again and its impact on PTON's future performance. In response, Peloton stressed at the JMP Securities Technology Conference on March 1, 2021 that exercising at home \"is a trend that's here to stay\" and \"COVID just accelerated that trend.\" The company also added that \"people have found a way not only to replicate exercising outside of the home, but enjoy it more and perhaps are doing even more than they were even pre-pandemic\", based on its analysis of members' data.\nNevertheless, it remains a significant unknown as to how consumers' behaviors will change and evolve post-pandemic.\nSecondly, Peloton has faced challenges in converting all of the consumer demand for its Connected Fitness products into actual sales.\nAt the company's 2Q FY 2021 results briefing on February 4, 2021, Peloton acknowledged that \"our delivery wait times remain elevated.\" It also highlighted that \"West Coast port delays and COVID-related delivery challenges\" resulted in longer-than-expected \"order to delivery wait times\" and \"forced us to reschedule many deliveries.\"\nBut Peloton is actively trying to address these issues. On April 1, 2021, Peloton disclosed that it had completed the acquisition of Precor, which it refers to as \"one of the largest global commercial fitness equipment providers with a significant U.S. manufacturing presence.\" This should help to ease Peloton's production capacity issues. Also, Peloton has also committed to an additional investment of $100 million with the aim of restoring delivery wait times to normalized levels by end of FY 2021 (June 30, 2022) at the latest.\nThe key concerns here are that this could result in significant customer dissatisfaction and also lead investors to turn to other alternative options such as going back to the gyms (if possible) or buying other competing home fitness products.\nThirdly, Peloton's stock price has been affected by product safety issues raised by the Consumer Product Safety Commission or CPSC.\nThe CSPC published a press release on April 17, 2021 \"warning consumers about the danger of popular Peloton Tread+ exercise machine after multiple incidents of small children and a pet being injured beneath the machines.\" Peloton has responded with a media release of its own on the same day, stating that the CSPC press release is \"inaccurate and misleading\". The company also emphasized that \"there is no reason to stop using the Tread+, as long as all warnings and safety instructions are followed.\"\nPeloton's share price fell by -7% from $116.21 as of April 16, 2021 to $107.75 as of April 19, 2021 following CSPC's press release and Peloton's response. The company has an incredible brand and a strong following as evidenced by some of its fans having Peloton tattoos, so it might take more than a warning from the CSPC to hurt its future sales. However, it is worth following the developments relating to this matter on product safety issues to evaluate any potential damage to Peloton's brand.\nIn a nutshell, the most important issue for long-term investors in Peloton is how consumers' attitudes towards home fitness & exercise will change post-COVID, which will affect the company's future growth runway. On the other hand, product delivery bottlenecks should be resolved in time to come, while the product safety concerns could blow over soon as well.\nHow Is Peloton Doing Financially?\nPeloton Interactive, Inc reported its most recent 2Q FY 2021 financial results (October 1, 2020 to December 31, 2020 period) on February 4, 2021. The company's financial performance in the second quarter of the current fiscal year was above market expectations.\nPTON's revenue rose by +128% YoY from $466 million in 2Q FY 2020 to $1,065 million in 2Q FY 2021, which was approximately +3% better that what Wall Street had expected. This was driven by a +124% YoY increase in Connected Fitness product sales and a +153% YoY growth in subscription revenue. The company also reversed from a net loss per share of -$0.20 in 2Q FY 2020 to a positive earnings per share of $0.18 in 2Q FY 2021. This was more than double the sell-side analysts' quarterly consensus earnings estimate of $0.08 per share.\nHowever, Peloton's share price declined by -6% from $157.53 as of February 4, 2021 to $148.30 as of February 5, 2021 post-results. The company's stock price subsequently dropped to a year-to-date low of $101.35 on March 8, 2021. This suggests that Peloton's financial performance might not be as good as what it appears on paper, if one delves deeper.\nNotably, Peloton's YoY revenue growth narrowed significantly from +232% YoY in 1Q FY 2021 and +172% YoY in 4Q FY 2020 to +128% in 2Q FY 2021. PTON is guiding for $1.10 billion in revenue for 3Q FY 2021, which translates to a top line growth of +110% YoY in the next quarter. This could be attributable to both product delivery issues and demand normalization (highlighted earlier), but there is no escaping the fact that Peloton's revenue growth is slowing.\nIn terms of operating metrics, it is noteworthy that the average workouts per month per subscribers for PTON has stabilized at 20.7 and 21.1 for 1Q FY 2021 and 2Q FY 2021 respectively. In comparison, Peloton's average workouts per month per subscribers jumped from 17.7 in 3Q FY 2020 to 24.7 in 4Q FY 2020. This could be another sign that home fitness demand is starting to normalize.\nPTON Stock Analysis\nThere are a number of things that investors should like about Peloton Interactive, Inc as a business.\nOne key characteristic of PTON's business is that the company has an amazing brand. As I indicated earlier, some of Peloton's followers even have the brand's logo tattooed on their bodies, which is the clearest indication of Peloton's brand equity. Also, consulting firmProphetnamedPeloton as the second most relevant brand in the US in 2021 based ona survey of approximately 13,000 consumers. Peloton only ranked behind Apple(NASDAQ:AAPL), and it beat other household brands like Lego, Costco(NASDAQ:COST)and Amazon(NASDAQ:AMZN). Prophet's studyhighlightsthat PTON \"earns the highest score for 'connects with me emotionally' via \"its online communities and its constantly expanding variety of workouts available live and prerecorded.\"\nAnother key characteristic of Peloton's business is that it offers a compelling value proposition for consumers. A Connected Fitness subscription costs $39 per month, and the company's Connected Fitness products like bikes are priced at around a few thousand dollars ($1,895for flagship bike product) which can be paid in installments and used by all the people living together. In other words, the all-in cost of working out at home by using PTON's products and services are much cheaper than an annual individual gym membership subscription. In addition, an April 9, 2021Wall Street Journalarticlecited Credit Suisse sell-side research which suggested that \"the monthly cost\" of \"a Peloton bike with a digital membership\" for a couple is \"87% below the cost\" of \"10 SoulCycle classes a month.\" Notably, Peloton's Average Net Monthly Connected Fitness Churncalculated as\"cancellations, net of reactivations\" divided by the number of Connected Fitness subscriptions was below 1% for both FY 2020 and FY 2019.\nMoving forward, Peloton has a long growth runway ahead, considering its multiple growth drivers.\nOne growth driver is new products and cross-selling. It is telling that only3%of Peloton's Connected Fitness' subscribers have both Bike and Tread products from the company. PTONobservedat the recent earnings call that there has been a \"continued mix shift to (the new) Tread products\" andmentionedat the JMP Securities Technology Conference that \"two-product households\" are \"more engaged than people who had have 1 piece of equipment.\" Looking ahead, it is likely that Peloton can increase the proportion of its subscribers who have bought both the Bike and Tread products, and such \"two-product households\" could also be interested in more fitness courses and programs offered by the company leading to higher subscription revenue as well.\nAnother key growth driver is potential synergies associated with the acquisition of Precor highlighted above. Although Peloton has a significant US consumer presence, it is not as strong in commercial and international markets, and Precor could help to fill in the gap. In the company's earlier press release announcing the Precor acquisition, Pelotonnotednew growth opportunities in channels like \"hotels, multifamily residences, and college and corporate campuses.\" Also, while Peloton generated 95% of its 1H FY 2021 revenue from North America as highlighted earlier, Precor hasa presencein \"90 countries around the world.\" PTON has already expanded into the UK and Canada, but there is a lot of room for further overseas expansion.\nOn the flip side, the huge growth potential of the home fitness market inevitably attracts competition. One key competitor isMirrorreferred to as an \"interactive smart gym\" enabled by \"advanced camera technology and machine learning\", The Mirror is , which Lululemon(NASDAQ:LULU)acquired inmid-2020. Another one of Peloton's key competitors isTonal, which calls itself \"an all-in-one machine\" combining \"fitness and strength training with patented digital weight, machine learning, and expert coaching.\" Tonal has raised$450 millionin cumulative funding since its launch, and one of its notable investors include Amazon’s Alexa Fund.\nWhile I acknowledge that Peloton has a strong brand, the competitive landscape in the home fitness industry is still relatively unsettled. The market is growing, and one can't rule out more new entrants. More importantly, customer switching costs (i.e. a few thousand dollars for the Connected Fitness products) might not be sufficient to prevent consumers from switching to new products and other alternatives.\nShould You Buy Peloton Stock?\nI see Peloton stock as a HOLD, rather than a BUY. While Peloton is a good company, it is not a good investment as it stands now. PTON's valuations are rather rich, considering that the company still generates more than 80% of its sales from products, rather than digital subscriptions.\nThe market values Peloton at 7.3 times consensus forward FY 2021 Enterprise Value-to-Revenue and 5.3 times consensus forward FY 2022 Enterprise Value-to-Revenue. The stock also trades at consensus forward FY 2021 and FY 2022 EV/EBITDA multiples of 91.8 times and 50.9 times, respectively.\nNone of Peloton's direct peers are listed on a stand-alone basis, which makes peer valuation comparison challenging. PTON is much more expensive than its fitness peers based on forward EV/EBITDA multiples, although there is a significant divergence in Enterprise Value-to-Revenue ratios for the peer group.\nPeloton's Peer Valuation Comparison\nSource: Author\nI have sourced the consensus numbers referenced in this article from S&P Capital IQ.\nPeloton's key risk factors are a more significant normalization of home fitness demand post-COVID than earlier anticipated, further negative news flow relating to product safety issues, and stiffer-than-expected competition from rivals in the home fitness industry.","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378190947,"gmtCreate":1619008204589,"gmtModify":1704718193406,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Love this","listText":"Love this","text":"Love this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378190947","repostId":"2129087941","repostType":4,"repost":{"id":"2129087941","kind":"highlight","pubTimestamp":1619006100,"share":"https://ttm.financial/m/news/2129087941?lang=&edition=fundamental","pubTime":"2021-04-21 19:55","market":"us","language":"en","title":"3 Stocks That Offer Explosive Potential Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2129087941","media":"Motley Fool","summary":"All of these companies have major catalysts ahead of them.","content":"<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.</p><p>These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.</p><p>Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker <b>NIO</b> (NYSE:NIO), EV charging network leader <b>ChargePoint Holdings</b> (NYSE:CHPT), and North American steelmaker <b>Nucor</b> (NYSE:NUE) could produce significant gains for shareholders in the years ahead.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fnioet7-hero-design.png&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"435\" referrerpolicy=\"no-referrer\"></p><p>The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.</p><h2>NIO: A massive and growing market</h2><p>As recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.</p><p>EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.</p><p>The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.</p><p>The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with<b> Ford</b> (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.</p><p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F619521%2Fchargepoint-ev-charging-for-multi-family1-copy.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p><p>Image source: ChargePoint.</p><h2>ChargePoint: A network of vital infrastructure</h2><p>With more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.</p><p>It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.</p><p>President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.</p><p>Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. <b>General Motors</b> (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.</p><h2>Nucor: New records on the horizon</h2><p>Leading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"</p><p>There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be <a href=\"https://laohu8.com/S/AONE\">one</a> of the biggest beneficiaries of this as <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top two low-cost steel producers in the U.S.</p><p>Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.</p><p>But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks That Offer Explosive Potential Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks That Offer Explosive Potential Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-21 19:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NUE":"纽柯钢铁"},"source_url":"https://www.fool.com/investing/2021/04/21/3-stocks-that-offer-explosive-potential-gains/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2129087941","content_text":"Investors looking for stocks with explosive growth potential sometimes seek out companies in sectors like biotech, where the outcomes can be almost binary. In the realm of cutting-edge healthcare, each hopeful new product or treatment will either be a success that could lead to monster profits, or fail to pass regulatory muster and earn nothing. Enough failures, and such companies' stock prices can go to zero.These three companies, on the other hand, have massive growth opportunities, but much less of that all-or-nothing risk. They either have successful businesses already, or are quickly growing in sectors that seem to have unstoppable momentum.Some of the catalysts that will be driving their share prices are more short term, while others will likely take years to play out. But there are good reasons to expect that electric vehicle (EV) maker NIO (NYSE:NIO), EV charging network leader ChargePoint Holdings (NYSE:CHPT), and North American steelmaker Nucor (NYSE:NUE) could produce significant gains for shareholders in the years ahead.The NIO ET7 electric luxury sedan is expected to be available starting in 2022. Image source: NIO.NIO: A massive and growing marketAs recently as early 2020, Shanghai-based NIO was flirting with bankruptcy. But a push by the Chinese government to accelerate the growth of that country's EV industry contributed to a strong surge in sales. The company more than doubled its vehicle deliveries in 2020 compared to 2019, though that still only amounted to about 44,000 electric cars. Its production growth rate is accelerating, however. In the first quarter of 2021, deliveries soared by more than 400% year over year to over 20,000.EV sales in China surpassed 1 million in 2020, and the government's goal is to expand that annual number to 5 million by 2025. According to a forecast from sector research organization BloombergNEF, China's EV sales could reach 10 million by 2030, and approach 20 million by 2040.The opportunity that degree of market growth represents hasn't been lost on investors. NIO stock is up more than 1,000% since its period of financial struggles a year ago. But its shares are also down by more than 40% from their recent peak. NIO's current $60 billion market capitalization is still pricing in an enormous amount of anticipated growth.The automaker will begin selling its ET7 luxury sedan early next year, and it recently announced plans for a new production factory. Its unique battery-swap subscription service, and an agreement with Ford (NYSE:F) to allow Chinese Mach E buyers to use NIO's charging network, will also add to its revenue streams. It certainly won't happen overnight, but the stock has the potential to advance well beyond its current level if the company executes.Image source: ChargePoint.ChargePoint: A network of vital infrastructureWith more than 70% market share, ChargePoint is the North American leader in Level 2 charging networks, which use 240-volt power. ChargePoint is rapidly growing its charging station network in the U.S. and expanding in Europe. It expects sales of its charging ports to grow by seven times through 2026. Its comprehensive network of offerings also includes more than 2,000 publicly available fast charging stations. Its suite of products caters to the needs of EV fleet owners, parking operators, and consumers, as well as corporations and municipalities.It began trading publicly recently through a merger with a special purpose acquisition company (SPAC). However, unlike many of the startups that have followed that path in the past year, ChargePoint is already bringing in significant revenue: $146 million in its fiscal 2021, which ended Jan. 31.President Biden's proposed $2 trillion infrastructure package includes about $175 billion dedicated to the EV sector. This includes installing 500,000 charging stations and electrifying bus fleets and government vehicle fleets. But while ChargePoint supports the infrastructure bill, and would almost certainly be a beneficiary of its passage, the company doesn't need that catalyst for its charging network to grow rapidly.Major automakers are on the verge of greatly expanding their EV offerings, and some, including Ford and Volvo Car Group, have committed to going virtually all-electric by 2030. General Motors (NYSE:GM) is targeting 2035. The need for much more EV charging infrastructure is clearly coming, and ChargePoint is in a prime position to supply it.Nucor: New records on the horizonLeading steelmaker Nucor released an unusual note to investors in early February, predicting it would deliver record quarterly earnings in the first quarter. It later followed that with guidance that it was likely to set another new record in the second quarter. Specifically, the company said: \"Nucor has elected to provide this update due to what it sees as an unusually large gap between its internal forecast and the current mean estimate for its first quarter earnings.\"There are several factors driving that outperformance, with a confluence of pandemic-related supply-and-demand impacts resulting in significantly higher product pricing. In fact, the current prices of certain steel products are twice what they have averaged for most of the past seven years. Nucor will be one of the biggest beneficiaries of this as one of the top two low-cost steel producers in the U.S.Shares of Nucor have gained about 45% since the initial alert in February, so much of what is known has been priced into the stock. It's also likely that steel pricing will moderate. Global supply is currently strained due to high demand, but eventually, the arrival of more supply from cheaper foreign producers will drive prices down, or else some users will more aggressively seek alternative materials.But based on what Nucor has already told investors, there is still room for significant growth in the stock price. If management's current predictions materialize, Nucor will earn around $2 billion in the first half of 2021. Even if earnings are cut in half in the second half of the year, full-year net income of $3 billion would give it a forward price-to-earnings (P/E) ratio of under 8. For a stable, dividend-paying company like Nucor, that would qualify as explosive short-term growth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":378104931,"gmtCreate":1619008013823,"gmtModify":1704718190314,"author":{"id":"3573389351985325","authorId":"3573389351985325","name":"JMLD","avatar":"https://static.tigerbbs.com/7ece1174c760a66e396a89dbc600e828","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573389351985325","authorIdStr":"3573389351985325"},"themes":[],"htmlText":"Bring me the moon!","listText":"Bring me the moon!","text":"Bring me the moon!","images":[{"img":"https://static.tigerbbs.com/619105afbeb5fde5015b6a6bda2b1180","width":"1600","height":"2481"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/378104931","isVote":1,"tweetType":1,"viewCount":318,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}